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The present work focuses on the development of a monoclonal antibody-
based enzyme-linked immunosorbent assay (ELISA) to measure 6各 
hydroxycortisol in urine samples. A polyclonal antiserum (R1-2B) was first 
developed in this study to provide a screening method for specific anti-6-B-OHC 
antibody. The 6-R-OHC was conjugated to a carrier protein [(BSA), bovine 
serum albumin] by substitution ofa carboxymethyloxime (CMO) group at the C3 
position. The immunization of this 6-S-OHC conjugate gave rise to specific anti-
6-S-OHC antibodies in the rabbit. Results from the ELISA using polyclonal 
antibody (R1-2B) showed that the antibody titre of the assay was in 1:500,000 
dilution, the assay had a sensitivity of 1 ng/ml (p<0.05), and intra- and inter-
assay coefficients were 3.1% and 5.2%, respectively. The specificity of the 
assay was determined by hapten inhibition studies, where the antibody 
recognized 6-li-OHC at a concentration as low as 1 ng/ml with a maximum 
concentration of 100 pg/ml. Cross reactivity with three other structurally related 
steroids (cortisone, hydrocortisone and 6-B-hydroxycortisone) did not exceed 
5%. The accuracy of this assay against 6-R-OHC was found to be comparable 
to other methods using radioimmunoassay (RIA) [0.025 ng/ml (Park 1978)]， 
ELISA [0.075 ng/ml (Shehnaz et a/” 1994)] and high performance liquid 
chromatography (HPLC) [0.68 ng/ml (lnoue et a/., 1994)]. Therefore, the ELISA 
method based on this antiserum was sufficiently specific and sensitive as a 
screening test for the development of monoclonal antibody against 6-l^-OHC. 
ii 
The polyclonal anti-6-B-OHC antibody-based ELISA was also used to measure 
6-B-OHC in man. The changes in 24 hours urinary 6-R-OHC concentrations 
were investigated using rifampicin (600 mg/day for 4 days), a well known 
enzyme inducer given to volunteers. The total urinary 6-S-OHC concentration 
collected in 24 hours was increased from 370 土 105 pg (controls) to 1350 土 201 
[sg (samples). These values were consistent with results from previous studies 
using RIA (Ohnhaus et al., 1989; Bammel et al., 1992). In animal studies, 
administration of rifampicin also caused a significant enzyme induction as 
indicated by the increased total 24 hours urinary 6-S-OHC concentration. 
Enzyme inhibitors，such as ketoconazole, cimetidine and nifedipine decreased 
the total 24 hours urinary 6-B-OHC output in rat and human urine. These 
results confirmed the results from previous studies that these drugs can affect 
the CYPIIIA4 activities. 
Monoclonal anti-6-B-OHC antibodies were subsequently developed, 
using the polyclonal antibody-based ELISA as a screening method for specific 
anti-lgG against 6-B-OHC. Two hybridoma clones, 5C1 and 19F which secrete 
anti-6-S-OHC monoclonal antibodies were developed, following fusion of NS-1 
myeloma cells and spleen cells from C57 mice immunized with 6-li-OHC-3-
carboxymethyloxime-bovine serum albumin. The antibody titre of clone 19F 
was as low as 1 in 5x10^ dilution, with sensitivity of 200 ng/ml (p<0.05) and 
intra- and inter-assay coefficients were 6.4 % and 7.3 %, respectively. The 
specificity of the assay was confirmed by hapten inhibition studies, where the 
antibody recognized 6-R-OHC at a concentration as low as 0.2 Mg/ml with a 
iii 
maximum concentration of 20 ^jg/ml. Cross reactivity with other three 
\ 
structurally related steroids (cortisone, hydrocortisone and 6-S-
hydroxycortisone) did not exceed 10 %. In contrast, monoclonal antibody 19F 
and polyclonal antiserum R1-2B exhibited similar specificity and sensitivity to 6-
R-OHC. Clone 5C1 was less specific than clone 19F to &-R-OHC and exhibited 
an unexpectedly high cross reaction with 6-R-hydroxycortisone (CR% = 100%). 
Therefore, monoclonal antibody clone 19F was used for the detection of 6-Q>-
OHC concentration. The ELISA based on this antibody (clone 19F) was then 
used to quantify the 6-S-OHC concentration in human and rat urine. Like 
antiserum R1-2B, the ELISA based on the monoclonal antibody 19F was 
comparable in accuracy with previous analysis by polyclonal antibody (R1-2B) 
based-ELISA in detecting the level of 6-R-OHC in urine samples from human 
volunteers and rats given one enzyme inducer and various inhibitors described 
as above. It can be concluded that the currently developed ELISA for 6-S-OHC, 
using either polyclonal and monoclonal antibody 19F, provide a rapid and 
accurate method, which would be ideal for routine measurement of 6-S-OHC in 
urine samples. Although the monoclonal antibody 19F only exhibited a similar 
sensitivity and specificity as polyclonal antiserum R1-2B, the antibody 19F had 
some real advantages over the antiserum R1-2B in that high background 
interference observed in the polyclonal antibody based ELISA can be avoided 
with the use of monoclonal antibody 19F. With their unlimited supply and their 
activity remaining constant over a long period of time, the standardization of the 
ELISA would be better with the monoclonal antibody 19F polyclonal antiserum 
R1-2B. Therefore, the use of this monoclonal antibody-based ELISA method 
iv 
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Abbreviations 
BSA Bovine serum albumin 
C-DME Complete Dulbecco's modifed Eagle's medium 
CMO Carboxymethyloxime 
CR % Percentage cross reactivity 
D-PBS Dulbecco's phosphate buffered saline 
DME Dulbecco's modifed Eagle's medium 
DMSO Dimethyl sulfoxide 
ELISA Enzyme-linked immunosorbent assay 
FBS Fetal bovine serum 
FCA Freund's complete adjuvant 
FIA Freund's incomplete adjuvant 
GC/MS Gas chromatography/mass spectrometry 
y-GT Glutamyltransferase 
HAT Hypoxanthine/aminopterin/thymidine 
HPLC High Performance Liquid Chromatography 










human serum albumin conjugate 
IC50 Concentration at 50% inhibition 
lgG Immunoglobulin G 
Mab Monoclonal antibody 
NADPH Nicotinamide adenide dinucleotide phosphate 
NS-1 Myeloma P3/NS1/1-Ag4-1 (ATCC No. TIB 18) 
OPD o-Phenylenediamine 
OVA Ovalbumin 
PBS-Tween Phosphate buffered saline with Tween 20 






In mammals, most drugs and environmental chemicals undergo 
extensive biotransformation before they are excreted. The liver is the 
principal site ofdrug metabolism, although other tissues such as white blood 
cells, placenta, skin, kidney, lung and especially the gut may also play an 
important role in the metabolism of drugs. The fundamental role of drug 
metabolism is the conversion of lipophilic compounds (such as drugs, toxins 
and endogenous substances) into more water soluble metabolites which are 
readily excreted. This limits the accumulation of these compounds in the 
body which may lead to disruption of normal cellular activity and potential 
toxicity (Jordan and Woolf, 1987). Drug metabolism occurs in two phases. In 
phase I reactions, hydrophobic substrates are rendered more water-soluble 
by the introduction of polar groups by oxidation, reduction or hydrolysis. The 
metabolic intermediates produced in these reactions may undergo phase 
two reactions. Phase 11 reactions involve conjugation of polar groups with 
water-soluble substances such as glucuronic acid, glutathione and sulphate. 
Most conjugated molecules produced in these reactions are 
pharmacologically inactive and readily excreted. Both phase I and II 
1 
reactions are catalyzed by drug-metabolizing enzymes, such as cytochrome 
P450, reductases, hydrolases for phase I reaction. In phase II reactions, 
epoxide hydrolases, glutathione S-transferases, glucuronosyl transferases 
and acetyltransferases are the major enzymes in conjugation reactions (Fig. 
1.1). 
1.2 Enzyme induction and enzyme inhibition 
The drug metabolizing enzyme systems are influenced by numerous 
external and physiological factors including age, sex, dietary constituents, 
smoking and co-administration ofdrugs. Enzyme activities may be increased 
following co-administration of certain xenobiotics. This enzyme induction 
results from the selective increase in the amount of drug metabolizing 
enzyme (Goldberg, 1980). Likewise the activity of the hepatic drug 
metabolizing enzymes may be decreased following administration of certain 
drugs (Batt, 1990). This usually involves a direct effect of the drug on the 
enzyme and is termed enzyme inhibition. 
The enzymes involved in enzyme induction and enzyme inhibition by 
drugs include multiple forms of cytochromes P-450, UDP-
glucuronosyltransferases, glutathione S-tranferases, y-glutamyltransferases 
and epoxide hydrolases. A large number of molecular forms of these 












































































































































































































































metabolism (Batt et al., 1992). Enzyme induction and enzyme inhibition 
most commonly occurs in the liver, but also occurs in other organs, such as 
lung, placenta and lymphocytes (Batt et ai, 1992). Over the past two 
decades, a variety of drugs and environmental chemicals have been 
identified as enzyme inducers or enzyme inhibitors (Table 1.1) and it is very 
likely that more agents will be discovered in the future. 
1.3 The consequences of enzyme induction and enzyme inhibition 
The consequences of enzyme induction and enzyme inhibition will be 
determined by the relative activity of the parent drug and the formed 
metabolite. Usually the metabolite will be less active than the original 
compound and therefore enzyme induction will result in a reduction in the 
pharmacological effect due to the increased drug metabolism. Enzyme 
inhibition would result in an increased concentration of parent drug at the 
receptor site and hence an increase in drug action. Also the metabolite 
formed during the bio-transformation may be chemically reactive which may 
bind covalently to proteins, membrane components, or nucleic acids, e.g. 
cyclophosphamide to aldophosphamide, prednisone to prednisolone and 
hence leading to cytotoxicity, mutations and/or cancer (Bolt et al.，1975; 
Allan et ai, 1990). 
4 
Table 1.1 Some enzyme inducers and enzyme inhibitors (Barry and Feely, 
1990) 
Enzyme lnducers:-
Barbiturates Marijuana smoke 
Carbamazepine Meprobamate 
Cigarette smoke Phenytoin 
Dichloralphenazone Primidone (phenobarbitone) 




















Another major factor which leads to the realization of the significance 
of enzyme induction and enzyme inhibition in man is the common practice of 
polypharmacy. The drug-drug interactions observed have produced many 
relevant examples of the processes of enzyme induction and enzyme 
inhibition. In the clinical setting，interactions involving drugs with a narrow 
therapeutic index，such as oral anticoagulants and antiepileptics will be of 
greater importance as moderate changes in drug metabolism could result in 
significant changes in pharmacological activity (Barry, 1990). The effects of 
enzyme induction and enzyme inhibition are reversible on withdrawal of the 
inducing or inhibiting compound although the rate of onset and offset of 
these processes may differ (MacDonald and Robinson, 1968). 
1.4 Induction of cytochrome P450 enzymes 
In man, multiple cytochrome P450 (CYP 450) enzymes are abundant 
in the liver, mainly in the endoplasmic reticulum. The mono-oxygenases 
involved in the oxidation of xenobiotics such as drugs and environmental 
substances, are probably the most important sub-group (Guengerich, 
1992a). The inducibility of these enzymes, following exposure to different 
drugs and chemicals, is the main feature of these enzymes (Distlerath and 
Guengerich, 1987). From the large number of cytochrome P450, a few are 
known to be inducible. At least five distinct patterns of P450 enzyme 
6 
induction have been found. They are characterized by protein purification 
and/or at the gene level by cloning the corresponding cDNA, as well as after 
exposure to model inducers. They include CYP IA (polycyclic aromatic 
hydrocarbon-type), CYP IIA (phenobarbital-type) CYP IIIA (steroid or 
pregnenolone 16-carbonitrile-type), CYP IIE (ethanol-type) and CYP IV 
(clofibrate-type) (Brockmoller and Roots, 1994). The human CYP IA1 is 
barely present or inducible in the human liver, but is characteristic of 
extrahepatic organs. It is induced by the polycyclic aromatic hydrocarbons 
(Omiecinski et al.，1990) and is associated with the health risks of smoking. 
Among therapeutic drugs, a planar configuration of the molecule appears to 
be important for induction, as in the benzimidazole anti-ulcer drug, 
omeprazole (Diaz et al., 1990). CYP IA2 (Butler et al., 1989) is also 
inducible by omeprazole, smoking and polycyclic hydrocarbons. Initially 
known as CYP-phenacetin it oxidises theophylline (Robson et al., 1988), 
caffeine, paracetamol (Raucy et al” 1989) and some carcinogenic 
compounds. 
Cytochrome CYP IIA3, which catalyses 7-hydroxylation of coumarin, 
shows considerable inter-individual variation (Yamano et al., 1990). Its 
inducibility was unknown until recently, although phenobarbital could induce 
activity, accounting for the accelerated loss of efficiency of coumarinic drugs 
in barbiturate-treated patients. Dexamethasone is also able to induce this 
activity. (Batt et al., 1992). 
7 
CYP IIE1 is a major catalyst for the oxidation of benzene, styrene, 
carbon tetrachloride, chloroform and other chlorinated solvents, vinyl 
chloride or bromide, alcohols, acetone, ethers, aniline and drugs such as 
paracetamol, enflurane, chlorzoxazone (Peter etal” 1990) and carcinogenic 
compounds such as A/-alkylnitrosamines (Yoo et al.; 1989). Ethanol 
(Wrighton et aL, 1986)，pyridine, acetone and pyrazole are the main 
"inducers" without increase in mRNA, either by increasing the translatable 
RNA, or by stabilizing the protein (Song etal.，1987). 
The human CYP IIIA gene subfamily appears to contain at least five 
genes: IIIA3, IIIA4, IIIA5 expressed in adult liver and IIIA7, IIIA8 present in 
fetal liver. CYP IIIA4 is inducible by barbiturates, dexamethazone or other 
glucocorticoids, rifampicin and erythromycin (Guengerich etal.，1989). It is 
unclear whether CYP IIIA3 and/or IIIA5 are inducible or not. CYP IVA, 
characterized as a 12-hydroxylase towards lauric acid, is expressed in the 
human liver. Its inducibility by fibrates has been widely reported in rats only 
(Chinje et al.，1991) but not in humans. 
1.4.1 CytochromeP450IIIA 
Cytochrome P450 belonging to the CYP IIIA gene subfamily accounts 
for up to 25% of the total cytochrome P450 present in human liver and is 
8 
found to be one of the most abundant forms of P450. (Guengerich et al., 
1986b). The importance of these enzymes is best established with respect 
to the metabolism of xenobiotics, particularly for drugs. The number of drugs 
metabolized specifically by CYP IIIA enzymes is now expanding rapidly and 
includes a wide variety of compounds in many therapeutic classes such as 
erythromycin, benzphetamine, aldrin, quinidine, cyclosporin, lidocaine and 
nifedipine (Guengerich et a/’ 1992a; Kronbach et a/，1988; Wrighton et a/， 
1989). These enzymes also play potentially important roles in the 
metabolism of ubiquitous and potentially harmful dietary contaminants 
(Guengerich, 1992b). 
In addition, there is an untested hypothesis that inter-individual 
variability in expression of these enzymes may exist. This probably explains 
in part the inter-individual difference in susceptibility to toxicity from those 
xenobiotics which are substrates for CYP IIIA enzymes (Guengerich et al., 
1992a). It may be possible to reduce an individual's risk from a toxic CYP 
IIIA substrate by treating the individual with safe drugs known to influence 
the regulation of CYP IIIA enzymes (i.e. therapeutically regulate the CYP 
IIIA enzyme involved up or down and thereby assure safe 'handling’ of the 
xenobiotic by the body). 
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1.5. Methods for assessing enzyme induction and enzyme 
inhibition 
Since enzyme induction and enzyme inhibition may greatly influence 
the drug metabolism systems, assessment of these processes is essential in 
drug development and drug safety evaluation. The principal methods used 
for the assessment of enzyme induction and inhibition to date can be divided 
into five main categories, they are: 1) Analysis of drug metabolism in vitro, 2) 
Determination of the pharmacokinetics of model drugs, 3) Substrate breath 
tests, 4) Measurement of the changes in endogenous substances level 
which reflects either the activity or the turnover of the enzyme of interest and 
5) Molecular biological techniques. 
1.5.1 Analysis of drug metabolism in Vitro 
It is obvious that if one wishes to investigate hepatic drug metabolism 
then the best model is the liver itself. Surgical removal of part of the liver and 
subjecting it to tests of the drug-metabolizing ability is a direct and ideal way 
of obtaining information on drug metabolism in man. It is therefore clear that, 
for the assessment of enzyme induction and enzyme inhibition in man, in 
vitro study by direct measurement of enzyme activity from liver biopsy 
samples before and after administration of an inducing/inhibiting compound 
1 0 
is an ideal method. However, there are two main problems which restrict the 
use of such direct studies in man: 1) ethical considerations and 2) practical 
considerations (Sesardic et al” 1988). For the former, the first question is 
whether it is ethically acceptable to take a liver sample from a healthy 
volunteer considering the risks involved in such a procedure? The widely 
* 
held view is that it is not acceptable to do so, and it is only acceptable to 
obtain human liver biopsy material if it is suspected that something is wrong 
with the liver. This therefore means that the liver samples taken from 
patients may contain infected tissue which therefore makes interpretation of 
data and extrapolation to the normal human situation difficult. Furthermore, 
the only time when "normal" liver does become available is from individuals 
who have died of non-liver-related cause, e.g. died from rejections, during 
kidney or heart transplant operations (from the donor), however, this raises 
its own ethical problems of consent to remove a liver for medical research 
(Gibson and Skett, 1991). 
Despite these limitations, recently developed liver banks in various 
hospitals have made more liver samples available for investigation of drug-
metabolizing enzyme activities. Moreover, in the assessment of enzyme 
induction and enzyme inhibition in man, it is suggested that such direct in 
vitro methods are best studied in conjunction with in vivo studies. In such 
studies the initial observations can be made in vivo, and further more 
detailed investigation of enzyme activities can then be achieved by the in 
vitro methods. (Park and Kitteringham, 1990) 
11 
1.5.2. Determination of the pharmacokinetics of a model drug 
Over the past two decades, changes in the pharmacokinetics of a 
model drug (antipyrine, theophylline, chlorzoxazone, tolbutamide, caffeine, 
warfarin and propranolol) or changes in the rate of metabolite formation of 
the drug are studied by indirect methods to assess drug metabolizing 
enzyme activity (Vesell, 1979). An ideal model drug for assessing hepatic 
drug metabolizing activity must fulfill the following criteria (Wilkinson and 
Shand, 1975): 1) Its clearance from the plasma or the appearance of a 
metabolite should be directly related to the activity of the enzyme(s) 
responsible for its metabolism, 2) The pharmacokinetics of the drug should 
be as simple as possible, such as one or two compartmental, with ail 
elimination entirely dependent on hepatic metabolism but independent of 
liver blood flow or plasma binding protein, 3) all routes of metabolism and 
enzymes involved should be known and 4) the drug should be rapidly and 
completely absorbed (preferably 100%). 
The drug which comes nearest to this ideal is antipyrine. It fulfills the 
above criteria with almost complete hepatic metabolism, less than 10% 
plasma protein binding and less than 5% excreted unchanged in the urine. 
Also, its single compartment kinetics together with its relative ease of 
measurement in either plasma or saliva by gas liquid chromatography, 
radioimmunoassay or high performance liquid chromatography further 
1 2 
renders it a suitable model drug (Stevenson, 1977). The changes in 
antipyrine clearance and its half-life have been used extensively in the past 
20 years, as a good index of liver microsomal enzyme induction and 
inhibition (Wilkinson and Shand, 1975)，and a wide range of inducing agents 
including drugs, pesticides and nutrients have been shown to increase 
antipyrine clearance and decrease antipyrine half-life, while similar enzyme 
inhibiting agents have been shown to decrease antipyrine clearance and 
increase its elimination half-life (Table 1.2). Antipyrine also has a number of 
other advantages: 1) It is easily measured in body fluids after a dose that is 
pharmacologically inactive and 2) salivary pharmacokinetics are similar to 
plasma pharmacokinetics therefore saliva can be sampled instead of the 
more painful and potentially damaging venepuncture. 
One disadvantage of antipyrine as a model drug is that antipyrine 
itself is a mild enzyme inducer in man. It may therefore stimulate its own 
metabolism as well as the metabolism of other drugs, such as warfarin and 
diazepam (Bax et al.，1981; Ohnhaus and Park, 1979; Breckenridge et al., 
1971). Thus repeated measurements of antipyrine clearance within a single 
study cannot be used. The other disadvantage of antipyrine as a model 
inducer is that its clearance does not always correlate well with metabolism 
(clearance) of other drugs and therefore it is a poor marker of certain drug-
metabolizing enzyme activities. This can be explained by the existence of 
multiple forms of drug-metabolizing enzymes in the human liver. 
1 3 
Table 1.2 Substances which increase and decrease antipyrine half-life in 
man 
Drug Reference 
Increase Antipyrine Half-Life: 
Allopurinol Vesell et ai, 1970 
Levodopa Vesell et al., 1971a 
Norethynodrel and Mestranol Carter et al., 1974 
Disulfiram Vesell et aL, 1975 
Aminopyrine Vesell et al., 1976 
Delta-9-tetrahydrocannabinol Benowitz and Jones, 1977 
Cimetidine Serlin et al., 1979 
Propranolol Baxefa/.，1981 
Metoprolol Bax et al., 1983 
Decrease Antipyrine Half-Life: 
Phenobarbitone Vesell and Page, 1969 
Organochlorine compounds Kolmodine et al., 1969 
Ethanol Vesell et al., 1971 b 
Spironolactone Huffman et al., 1973 
Tricyclic antidepressants 0'Malley et al., 1973 
Phenytoin Petruch et al., 1974 
Quinine Berlin etal” 1975 
Testosterone Johnsen etal., 1976 
Rifampicin Miguet et aL, 1977 
Ascorbic acid Houston, 1977 
Glutethimide Jackson etal” 1978 
Carbamazepine Moreland etal” 1981 
1 4 
Measurement of the kinetics of antipyrine metabolites has also been 
used for assessing the activity of drug metabolizing enzymes. It has been 
suggested that the three major metabolites of antipyrine; norantipyrine, 4-
hydroxy antipyrine and 3-hydroxymethyl antipyrine, representing three 
separate processes are produced by different forms of cytochrome P-450 in 
man (Danhof et al” 1982). The measurement ofthe activities of the separate 
metabolic pathways is found to be more reliable for correlation studies than 
the overall rate of metabolism (Teunissen et aL, 1985). Antipyrine is thus a 
suitable model drug，to be used as a valuable index in the study of enzyme 
induction and enzyme inhibitionin man. 
Other drugs used as model drugs include diazepam, hexobarbitone 
phenylbutazone, phenacetin, quinine, propranolol, tolbutamide and warfarin. 
In addition, the latter three drugs allow the investigation on concomitant 
changes in pharmacodynamics (heart rate and blood sugar) (Barry and 
Feely, 1990). Like antipyrine, they all have limited predictive values in 
estimating how the liver will deal with other drugs. There is a recently 
developed cocktail approach, which involves the administration of more than 
one model drug simultaneously (nifedipine, sparteine and mephenytoin), 
and the subsequent measurement of plasma kinetics of drug and 
metabolite(s) and urinary excretion of unchanged parent compound and 
metabolite(s) (Breimer et al” 1990). This strategy has a practical advantage 
in being capable of detecting differential influences of induction and 
1 5 
inhibition on oxidative drug metabolizing enzyme activity in humans. This 
approach could also be useful in new drug development in order to assess 
whether or not a new compound will be a potential risk for drug-drug 
interactions through enzyme induction and enzyme inhibition. Rather than 
performing several single studies with different model drugs, the cocktail 
approach could allow sufficient information to be obtained in one 
experimental protocol. 
1.5.3. Breath test analysis 
Assessment of drug metabolism by breath analysis provides an 
alternative method of assessing possible enzyme inducers and inhibitors in 
man. This method relies on the breakdown of the administrated substrate to 
yield carbon dioxide (CO2) which is excreted via the lungs. The substrate is 
labeled with an appropriate radio-label (e.g. 14c) and the resultant 
radiolabelled [^^C]CO2 is excreted in the exhaled air which can be collected 
and measured. The substrate most commonly used in the past is 
aminopyrine, which is predominantly metabolized by the hepatic mixed-
function oxidase system by N-demethylation, and thus the aminopyrine 
breath test has been suggested as a useful indicator for assessment of this 
enzyme system (Hepner et a/.，1977). A correlation is observed between 
[14c]C02 excretion following administration of [1^c] aminopyrine and the 
1 6 
mass of hepatic microsomal mixed function monoxygenase system 
(Lauterburg and Bircher, 1976). 
In addition, the aminopyrine breath test has also been suggested to 
be a useful test in assessing enzyme induction caused by anticonvulsant 
drugs, therefore indicating that it is sensitive to changes in cytochrome P-
450 (Hepner et al., 1977). Furthermore, the aminopyrine test has been used 
to demonstrate the inhibitory effect of some known enzyme inhibitors (e.g. 
amiodarone and cotrimoxazole) on hepatic drug metabolism (Barry et aL, 
1986; Duenas-Laita et al.’ 1986). The disadvantage of the aminopyrine 
breath test is that it is only a useful index for a limited number of isoenzymes 
of the mixed-function oxidase system in the liver. Also, since the use of 
radiolabelled 14c may cause health problems, the use of 1^C non-
radioactive isotope substrate breath test would be a good alternative 
(Schneider et ai, 1978). 
More recently, other substrate breath tests which use radiolabelled 
[14c] N-methyl-erythromycin have been increasingly used to assess the 
activities of drug metabolizing enzymes. This erythromycin breath test has 
been proposed to be a specific index to measure in vivo CYP IIIA4 activity in 
liver (Kinirons et al., 1993). Furthermore, the other substrates which have 
been used in breath tests, included caffeine and diazepam, however, since 
they are similar to aminopyrine they may only be a model substrate for a 
1 7 
limited number of isoenzymes in the drug metabolizing system. They are 
rarely used to assess enzyme induction and enzyme inhibition in man. 
1.5.4. Measurement of changes in endogenous substrates 
Measurement of the changes in the disposition of endogenous 
compounds are regarded as useful non-invasive methods for the 
assessment of drug metabolizing capacity of the liver. These methods 
provided alternative routes to assessing enzyme induction and enzyme 
inhibition but without the requirement of administration of a test drug. The 
currently used non-invasive methods are: measurement of plasma y-
glutamyltransferase. plasma bilirubin, urinary 6-S-hydroxycortisol (6-R-OHC) 
and urinary D-glucaric acid. 
A) y-Glutamyltransferase 
y-Glutamyltransferase is an enzyme found mainly kidney, liver, 
pancreas and testes (Orulowski，1963). It catalyses the transfer of y-
glutamylpeptides from glutathione to other peptides or amino acids. 
Although it has been proposed that its function is not related to drug 
metabolism, increases in plasma y-glutamyltransferase concentrations have 
been found in patients who have received certain enzyme inducing agents 
1 8 
(Table 1.3) (Hildebrandt etal” 1975). Due to these observations, the plasma 
level of this enzyme can be used as an indicator of enzyme induction. 
However, other drugs not regarded as enzyme inducers also increased the 
enzyme level. Definitive studies have shown that a rise in plasma level of 
this enzyme is related to disturbance of the plasma membrane in the liver 
rather than to enzyme induction (Tazi et al.，1980). It has been shown that 
high levels of plasma y-glutamyltransferase are commonly found in patients 
with liver damage, high alcohol intake and pancreatitis (Barry and Feely, 
1990)，and thus this enzyme is not a good index for assessing enzyme 
induction in man. 
B) Plasma bilirubin 
Bilirubin is taken up by hepatocytes where it is conjugated with 
glucuronic acid and excreted into bile. The estimation of plasma bilirubin has 
been studied in relation to drug metabolism. A significant decrease in 
plasma bilirubin was found to accompany administration of certain enzyme 
inducing drugs in patients (rifampicin, phenobarbitone and phenytoin). A 
significant correlation between plasma unconjugated bilirubin and antipyrine 
half-life was also found (Scott et al” 1979). However, since plasma 
concentrations are also under the influence of diet, diseases and diurnal 
variation, plasma bilirubin is therefore an unreliable index of enzyme 
induction (Hunter and Chasseaud, 1976). 
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Table 1.3 Substances which increase plasma y-GT concentration in man 
Drug Reference 
Anticonvulsants Rosalki et al., 1971 
Ethanol Rosalki and Rau, 1972 
Nitrazepam Whitfield et al.，1973 
Phenobarbitone Hildebrandt et al.，1975 
Antipyrine Ohnhaus and Park, 1979 
Rifampicin Back et aL, 1979 
lmipramine Tazi et al.，1980 
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C) Urinary 6-B-hydroxycortisol 
6-R-Hydroxycortisol is a polar metabolite of cortisol formed primarily in 
the endoplasmic reticulum of hepatocytes by the mixed function oxidases, 
which are also responsible for the metabolism of many drugs. The normal 
urine output of 6-B-hydroxycortisol is between 2 and 6% of total cortisol 
metabolites (Frantz et al” 1961). As its output was found to be increased by 
a number of enzyme inducing agents, the changes in urinary 6-R-OHC 
excretion have been suggested to be a useful and sensitive index of 
microsomal enzyme induction in man (Park, 1981). Some of the drugs and 
environmental chemicals which have been found to increase 6-S-OHC 
excretion are summarized in Table 1.4. More recently, the increase in this 
endogenous metabolite has been shown to specifically reflect the induction 
of human CYP IIIA (Maeupaa et al” 1993). Since the extent of 6-S-OHC 
production is mainly dependent on the daily cortisol formation which may be 
influenced by many factors including some physiological factors: sex, thyroid 
function, newborn, pregnancy and some pathological conditions: 
adrenocortical hyperfunction, liver disease and cancer (Touchstone et al” 
1961; Werk et al” 1964; Eade et al” 1977) and such inter-individual 
variations in 6-R-OHC production may be compensated for by referring 6-Q>-
OHC values to the total free cortisol value. Hence most of the studies have 
now focused on using 6-B-OHC/cortisol ratio in the assessment of enzyme 
induction (Saenger et al., 1983; Bienvenu et al., 1991). From a practical 
point of view, changes in 6-B-OHC output can be directly measured in urine 
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Table 1.4. Substances increasing the urinary excretion of 6-Q> hydroxycortisol 
in man 
Drug Reference 
Phenobarbitone Burnstein and Klaiber, 1965 
Phenylbutazone Kuntzman etal., 1966 
DDT Poland et al., 1970 
Pentobarbitone Berman and Green, 1971 
Spironolactone Huffman etal” 1973 
Antipyrine Davis et aL, 1974 
Carbamazepine Roots et al” 1979 
Rifampicin Davis etal., 1974 
Sulphinpyrazone Staiger et al., 1983 
Cyclosporin Kronbach et al.，1988 
Quinidine Guengerich et al., 1986b 
Phenytoin Fleishaker et al.，1995 
Pravastatin Karayalcin et al., 1991 
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samples and such measurement can also be used repeatedly throughout a 
study. The measurement of 6-B-OHC output therefore possesses as 
practical advantages over the model substrate clearance test. In addition, in 
comparison to other non-invasive methods for detecting enzyme induction, 
6-R-OHC is suggested to be a better index of microsomal enzyme induction 
than plasma bilirubin, y-GT or urinary D-glucaric acid excretion (Park, 1981). 
On the other hand, a decrease in the excretion of 6-S-OHC could also 
provide an index of enzyme inhibition. The excretion of 6-B-OHC has been 
shown to be decreased by several well known enzyme inhibitors including 
cimetidine (Vestal et al., 1987)，isoniazid (Brodie et al” 1981) and 
ketoconazole (Zurcher etal” 1989). 
D) Glucaric acid 
D-glucaric acid, first identified in human urine in 1963， is the end 
product of glucuronic acid metabolism produced via the glucuronic acid 
pathway, which is a metabolic route branching from glycogenolysis (Fig. 1.2) 
(Marsh, 1963). It has been shown that the increase in urinary D-glucaric acid 
followed microsomal enzyme induction caused by treatment with various 
well known enzyme inducing agents (Table 1.5) and this parameter has 
therefore been suggested to be an index for enzyme induction (Aarts, 1965; 
Dossing et al” 1984; Batt et al” 1992). The mechanism whereby enzyme 
induction results in increased D-glucaric acid production is not fully 
understood. It may be due to a feedback mechanism involving NADPH 
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Table 1.5 Some substances which increase urinary excretion of D-glucaric 
acid in man 
Drug Reference 
Aminopryrine Aarts, 1965 
Phenylbutazone Aarts, 1965 
Barbiturates Hunter et al” 1971a 
DDT Hunter et aL, 1971b 
Spironolactone Huffman etal” 1973 
Antipyrine Davis et al” 1974 
Phenobarbitone Lantham et al” 1975 
Carbamazepine Lai et al” 1978 
Rifampicin Ohnhaus and Park, 1979 
Miconazole Heinemeyer et al., 1986 
Neuroleptics Heinemeyer et a/.，1986 
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production in the pentose phosphate pathway, NADPH being required for 
the reduction of cytochrome P450. Alternatively, D-glucaric acid may be an 
index of phase two drug metabolism (Latham et al., 1975; Sjoqvist and von 
Bahr, 1973). 
A large inter-individual variation in the production of urinary D-glucaric 
acid has been observed. This limits the use of this parameter as the index 
for assessment of enzyme induction. In addition, there is little correlation 
between the urinary D-glucaric acid excretion and hepatic drug metabolism 
(Barry and Feely, 1990). The increases in D-glucaric acid excretion have 
been shown to be highly dependent on the dose of enzyme inducer; only 
little or no change in the production followed a low dose of phenobarbital (30 
mg) administration whereas there was a seven-fold increase with higher 
doses of phenobarbitone (300-500 mg/day) (Roots et al.，1977). Such low 
sensitivity reduced the utility of D-glucaric acid excretion as a method for 
detecting enzyme induction. 
1.5.5. Molecular biological techniques 
Molecular biological techniques are recently developed for the 
assessment of enzyme induction and enzyme inhibition. The best known 
molecular biological technique is based on the method of direct mRNA 
detection for the subsequent specific P450 enzyme. For example, specific 
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CYPIAI mRNA detection was performed using Northern Blot analysis or 
reverse transcription polymerase chain reaction (RT-PCR) (Omiecinski et al” 
1990; Sauer, 1991). These techniques are very attractive since they require 
only a few hundred blood cells for analysis. Furthermore, design and 
synthesis of specific genetic probes from known sequences is generally 
easier than generation of highly specific antibodies that are capable of 
differentiating between highly homologous enzymes. However, it is usually 
irrelevant in the selection of optimal enzyme induction parameters since the 
mRNA is formed prior to protein. Moreover, because of the higher stability of 
protein than mRNA, enzyme specific protein quantification would be 
analytically preferable (Diaz etal” 1990). 
A more recently developed technique for assessing enzyme induction 
is based on the gel shift assays which quantify the interaction of an enzyme 
inducer with a cytosolic receptor regulating CYP IAI enzyme expression 
(Puga et al., 1992). However, the methodology still needs to be optimized 
before it may be used in clinical studies or experimental studies to achieve 
a quantitative assessment of the inducibility ofdrugs. 
1.6. Analytical methods for detection of urinary 6-R-OHC in man 
Measurement of urinary 6-R-OHC in human urine has been shown to 
be a good non-invasive indicator of CYP IMA enzyme activities (Ged et al., 
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1989; Guengerich, 1992b; Bienvenu etal., 1991). The increased excretion 
of this endogenous steroid is also associated with adrenocortical 
hyperfunction (Touchstone et al., 1961)，toxemia (Frantz et al” 1960), liver 
disease (Eade et al., 1977), Cushing's syndrome (Nakamura et ai, 1985) 
and cancer (Werk et al, 1964). Thus, determination of the urinary level of 6-
R-OHC is of clinical significance. 
In choosing a suitable method for detecting the 6-l3-OHC 
concentration in urine, the method must be sensitive enough to detect this 
endogenous steroid at low concentrations, because only a relatively low 
concentration of 6-B-OHC is found in normal human urine (ranging from 
400-600 M9) (Ged et al” 1989; Ohnhaus et al” 1989). The method should 
also be specific enough to detect the steroid without detecting any 
structurally related steroids. Chromatography and immunoassay are the 
most commonly used methods and which have the sensitivity and specificity 
for screening urinary 6-ft-OHC levels. Chromatography, especially GC/MS 
and HPLC, are known to be among the most accurate analytical methods 
nowadays. However, these methods are usually complicated in practicality, 
such as extraction is required before the samples are analyzed. In contrast, 
immunoassays represent a good alternative for specific and sensitive 
detection, and with its simplicity in practice and low-cost, immunoassays 
could generally exhibit a real advantage over the chromatographic methods 
in the routine detection of 6-B-OHC concentration in human urine. 
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1.7. Antibodies for immunoassay system 
Conventional polyclonal antibodies are commonly used in 
immunoassays. Production of these antibodies requires immunization of 
host animals and collection of their sera. This antiserum ‘ is a mixture of 
antibodies containing a variety of molecules directed against the antigen. 
According to the clonal theory (Burnet 1968)，the antibodies are produced by 
different clones of antibody-producing cells of the host body. Each of these 
antibodies has its own characteristics and hence, the properties of a 
polyclonal antibody preparation is the summation of all these antibodies. 
Apart from their simplicity in production, the major advantage of these 
antibodies is that they react with their specific antigen to form large and 
detectable immune complexes, and this antigen-antibody reaction can be 
easily detected photometrically. High antibody titre is usually obtained in this 
conventional antibody preparation, which would allow the use of the 
antibodies in high dilution to minimize the background activity often 
observed in immunoassays. However, polyclonal antibodies have certain 
disadvantages: the major one is their heterogeneity in specificity, such that 
the antibodies may cause cross-reaction with antigens differing from the 
antigen of interest. In this way, the polyspecific property of polyclonal 
antibodies present a limitation for the development of immunoassays that 
require high specificity against the antigen. Moreover, the activity of the 





batches of immunogen used. This makes the standardization of 
immunoassays difficult. 
Monoclonal antibodies could be a useful alternative to polyclonol 
antibodies. The theory of monoclonal antibody production was originally 
presented by Kolhler and Milstein in (1975). Monoclonal antibodies are 
produced by somatic cell fusion between an antibody producing cell (B cell) 
and an immortal cancerous cell (myeloma); the hybrid formed will possess 
both characteristics (antibody production and immortality) of the parent cells. 
The hybrid can grow in culture indefinitely and produce only one kind of 
homogenous antibody with its unique properties. The monoclonal antibody 
can theoractically be obtained in unlimited amount, making the 
standardization of immunoassay possible. With its pre-defined specificity, 
cross reaction due to mixture of antibodies against irrelevant antigens could 
be eliminated or minimized. 
1.8. Production of polyclonal antibody and monoclonal antibody 
Certain important principles may be adopted as the ground rules in 
the production of polyclonal and monoclonal antibody in relation to the 
preparation of immunogen, immunization procedures and sample testing. 






1.8.1. Preparation of immunogen 
For a molecule to act as an immunogen and produce an antibody 
response, its molecular size has to be greater than 5,000. Molecules less 
than this minimum size limit are generally poor immunogens (Catty and 
Raykundalia, 1989). For these small molecules to induce an antibody 
response, they are usually conjugated to a larger molecule to increase their 
immunogenicity. Proteins are the most commonly used carriers, whereas 
those small molecules are defined as haptens (Roitt etal., 1989). 
The antibody responses are determined by the size, charge and non-
polar properties of the haptens, and are also influenced by the choice of 
protein carrier, the hapten density and uniformity of the hapten-carrier 
linkage. Therefore, in the preparation of a better immunogen for antibody 
production, it is necessary to prepare different conjugates with several 
different carriers, with different hapten-carrier coupling ratios, to allow the 
selection of a better constructed immunogen for antibody production. The 
functional group and coupling sites of the hapten involved in the conjugation 
reaction are also important and will affect antibody specificity. It is suggested 
that the coupling site of the hapten-carrier conjugate should be away from 
the recognization sites (Spector and Parker 1970; Bauminger et al., 1974). 
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Several approaches are available for the formation of hapten-carrier 
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conjugates, the most commonly used of which is based on the method of 
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Erlanger et a/.,(1957). In this approach, existing carboxylic acid groups on 
the hapten to form a peptide bond with the amino group of lysine residues in 
the protein carriers. For those haptens with no carboxylic group available to 
form a peptide bonding, a carboxylic acid group is introduced into the hapten 
before conjugation can take place. There is a wide variety of molecules with 
carboxylic acid group that can be introduced onto the hapten, including 
carboxylmethyl-oxime (CMO), (Erlanger et al., 1957)，hemisuccinate (Steiner 
et al., 1969)， carboxymethyl (Spector and Parker, 1970)， alkanamate 
(Robinson et al., 1975) and thioalkanoate (Rao and Moore, 1976). All these 
methods require activation of the introduced carboxylic acid group to 
maintain the hapten chemically unaltered and with its unique point of 
attachment clearly defined. These activation processes can be achieved by 
alkyl chloroformate (Erlanger et al., 1957) or with a soluble carbodimide 
(Bauminger et al., 1969). 
1.8.2. Immunization procedure 
After the synthesis of an immunogen, immunization process is carried 
‘ j： 
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out to produce the antibodies. There is no single method for animal 
immunization that guarantees an ideal product. However, certain principles 
ii 
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should be considered prior to the immunization step. The choice of an il 
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appropriate animal species as the recipient is the first consideration. Rabbits 
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routine production of antiserum. They are easy to handle for immunization 
and blood sampling. A relatively large amount of sera can be obtained from 
rabbits and the antibodies produced are well characterized, easy to purify 
and very stable in storage. Most of the laboratory rabbits are outbred and 
their antibody responses to immunogen may vary individually. Therefore 
several rabbits are usually used for immunization. The sera should be tested 
individually. For monoclonal antibody production, most work to date has 
been done with mice. This is because so much more is known about the 
use of mice and myelomas than with anything else, so if there is no 
particular reason for choosing another species the mouse should be used. 
The use of adjuvant is also important for a successful immunization. 
The essential properties should allow the enhancement of the antibody 
response in different ways (Catty and Raykundalia, 1989): 
1) They potentiate and increase the efficiency of antigen presentation 
and the number of collaborating and secreting cells involved， 
effectively reducing the optimum required immunogen dose. 
2) They prolong antibody responses by protecting the immunogen from 
rapid removal and breakdown; thereby reducing the number of 
repeated dosages. 
.i 
3) They increase the average avidity and affinity of the antibody | 
response. j 







The most commonly used adjuvant in animal immunization is 
Freund's adjuvant (Freund, 1956), which are very effective in routine 
antisera production to soluble antigens. The dosage and route of injection of 
the immunogen should also be considered as well as the immunization 
species, stage and volume of injection, desired rate of release, nature of 
immunogen and the use of adjuvant. For a soluble protein immunogen that 
is mixed with Freund's adjuvant, a dose of 0.5 - 1 mg/animal is 
recommended for rabbit immunization and 50 -100 pg/animal for mouse 
immunization (Harlow and Lane, 1988). For rabbit immunization, large 
volume injection and slow release of immunogens is desired for routine 
production, injections are normally given intramuscularly on both hind legs 
and also at multiple subcutaneous sites through the loose skin of the 
shoulders. For mice immunization, the immunization schedule used would 
depend on the nature of the immunogen just as is done in the preparation of 
polyclonal antiserum. After the initial injection, the prime antibody response 
of lgM production is often very weak, short lasting and even undetectable, 
and this prime response will establish the immuno-memory for this particular 
immunogen. When the immunogen is repeatedly administered to the animal, 
a secondary antibody response is produced faster, stronger, longer lasting 
and qualitatively different. This secondary antibody response will shift the 
antibody class from lgM to the lgG which is the most abundant class of 
antibody. Therefore, the responses of subsequent injections will be similar to 
j 
that of the secondary antibody response. In this way, the interval between i 
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the immuno-memory for a particular immunogen. The interval between the 
initial and other boosters given to mice and rabbit is recommended to be 4 -
6 weeks (Harlow and Lane, 1988). 
1.8.3. Screening test for antibodies 
When antibodies are used in quantitative immunoassay to measure 
small molecules, the first and the absolute requirement are their avidity and 
specificity. Testing for polyclonal antiserum produced after immunization is 
necessary to determine whether or not the antibody has the required 
specificity and sensitivity for the particular immunoassay. Moreover, the rise 
in antibody titre and changes in specificity and avidity after each injection is 
monitored to determine the batch of antiserum to be used. It is necessary to 
use a reliable screening test for the selection of the best responsive mice for 
hybridization, and also a screening test to determine whether the desired 
antibodies are secreted from the hybridoma clones. In principle, any assay 
capable to detecting the antibody-antigen reaction could be employed. RIA 
could be used, despite several drawbacks such as the short half-lives of the 
1 
gamma-emitting isotopes，radiation may cause structurally damage to the | 
antibodies, health hazards involved in handling of radioisotopes and a 
separation step which makes automation difficult. To avoid the use of 
radioactive substances and difficulties in separation, ELISA is a good 







exists in many different kinds of protocols which have specific application 
(Voller et al., 1979). It can be used to qualify or quantify both antigens or 
antibodies. Basically, ELISA exists in two forms, direct double-antibodies 
sandwich method for determining antigens and indirect method for 
determining antibodies (Fig. 1.3). In the direct method, 6ne kind of the 
antigen-specific antibody is immobilized to a solid support. After adding the 
test sample, a second antigen-specific antibody labeled with an enzyme is 
followed. Then, the activity of the enzyme, which has been immobilized to 
the solid support by the immuno reaction of the antibodies and antigen, will 
have a direct relationship to the amount of antigen in the test sample. In the 
indirect method, the antigen is coated to the solid support. Test samples 
with the specific antibody to the antigen will be added and a second anti-
immunoglobulin antibody (specific to the antibody of interest) labeled with an 
enzyme will be allowed to react. Similarly, the enzymatic activity immobilized 
will also reflect the amount of antigen-specific antibodies in the test sample. 
i' 
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Many anti-steroid antibodies produced by conventional methods have 
Rj 
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been reported to cross react with some of the endogenous steroids, such as 
testosterone (Abraham, 1975). Since a high degree of specificity is needed 
to measure 6-R-OHC in human urine by ELISA, monoclonal antibodies 
against the steroids would be the ideal probe for this purpose. In this study, 
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Figure 1.3.a. Indirect ELISA protocol: The antigen of interest is first 
immobilized to a solid support. After subsequent incubation of the 
test sample and a second anti-immunoglobulin antibody labelled 
with an enzyme, the activity of the enzyme retained on the solid 
support will be directly proportional to the amount of antigen-specific 
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Figure 1.3.b. Direct ELISA protocol: The antibody to the antigen is ！ 
first immobilized to a solid support. After subsequent incubation of 
the test sample and a second anti-immunoglobulin antibody 
labelled with an enzyme, the activity of the enzyme retained on the 
solid support will be directly proportional to the amount of antigen 
in the test sample. 
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monoclonal antibodies to 6-S-OHC have been prepared with a view to 
developing an ELISA suitable for the quantification of this steroid in urine 
samples. To provide a screening method for the specific anti-6-(i-OHC 
monoclonal antibody，polyclonal antiserum were first raised in rabbit. The 
antiserum would act as a reference to compare the specificity as well as the 
sensitivity of monoclonal antibody. 6-(i-OHC is a relatively small molecule 
and in order to induce antibody production in the host animal, it must be 
conjugated to a protein carrier, such as bovine serum albumin or ovalbumin, 
to increase its immunogenicity. The method of conjugation is modified from 
Jondorf (1977)，who has successfully raised antiserum against nandrolone, 
The steroid-protein conjugates synthesized are used for immunization as | 
well as the development of an ELISA to detect the subsequent anti-6-R-OHC i 
I 
activity. After both polyclonal and monoclonal antibody have been 
characterized, they are used to measure the amount of urinary 6-R-OHC in 
human and rat urine samples. The results are compared with those obtained 
from previous studies which will give the validation of the polyclonal and jj 
1 
monoclonal antibody in quantifying 6-R-OHC. 
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Chapter 2 
Development of Polyclonal Antibodies against 
6-K-hydroxycortisol and Its Applications 
2.1. Introduction 
6-R-Hydroxycortisol (6-S-OHC) is one of the unconjugated urinary 
metabolites of cortisol in human (Frantz etal” 1961). Measurement of 6-R-OHC 
in urine is regarded as a useful non-invasive method for detection of enzyme 
1 
！ 
induction in man. (Ged et al., 1989). It is suggested that urinary 6-S-OHC 
specifically reflects the human liver CYP IIIA enzyme activity (Waxman et a/.， 
1988; Ged etal” 1989; Maenpaa etal” 1993). The CYP IIIAfamily is clinically 
important, because they have been shown to metabolize a large number of 
drugs, for example: erythromycin, benzphenetamine, aldrin, quinidine, 
cyclosporin, lidocaine, dihydropyridine and calcium channel blockers such as ！ 
nifedipine (Guengerich et al., 1986b; Kronhach et al., 1988; Wrighton and } 
Vandenbranden 1989; Bienvenu et al., 1991). Measurement of the 6-R-OHC | 
is often expressed from a 24 hour urine collection as the ratio 6-R-OHC/free 
cortisol in order to adjust for minor day to day variation in adrenal cortisol 
metabolism. It has been suggested that this ratio can be determined from a 
single "spot" urine collection rather than 24 hour collection, because the ratio 
ofthese two parameters appears to remain reasonable constant throughout the 





The measurement of 6-B-OHC and free cortisol have been carried out 
by radioimmunoassay (RIA) (Park 1978; Kishida and Fukushima 1977) and/or 
high performance liquid chromatography (HPLC) (Nikamura et al 1985; Roots 
et a/.，1979; lnoue et al., 1994). The former, besides its difficulty in automation, 
poses a potential health hazard in handling of radioisotopes. The latter is time-
consuming and requires highly sophisticated instruments. However, a recently 
developed enzyme-linked immunosorbent assay (ELISA) using rabbit 
polyclonal smtibody (Zhiri et al., 1986; Shehnaz et al., 1994), requires only a 
simple spectrophotometer for detecting the enzyme activity and does not 
I 
require extraction, needing only simple dilution of the urine sample. The | 
sensitivity of ELISA in detecting urinary 6-R-OHC is reported to be as sensitive 
i' 
I 
as the HPLC and RIA (Shehnaz et a/_，1994). Hence, the detection of urinary 
6-S-OHC by ELISA may have advantages over RIA and HPLC as a simple, 
cheap, rapid and sensitive method for screening large numbers of samples. 
V 
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In this study, the main aim is to develop an enzyme-linked j 
immunosorbent assay (ELISA) for the detection of specific anti-6-R-
：! 
hydroxycortisol antibodies. Antibody against 6-B-hydroxycortisol (6-R-OHC) will | 
be raised in the rabbit. The proposed polyclonal antibody-based ELISA will be | 
： 
used to measure the urinary 6-S-OHC level in human and rat urine samples. 
In addition, the polyclonal antibody-based ELISA will also be used as a basis 
for the development of mouse anti-6-B-OHC monoclonal antibodies (Chapter 
3). Furthermore, the polyclonal antibodies may be used as a reference 
41 
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standard to compare the sensitivity and specificity of subsequent monoclonal 





















2.2. Materials and methods 
2.2.1 Reagents and apparatus 
Bovine serum albumin (fraction V; BSA), ovalbumin (grade V; OVA), 
human serum albumin (fraction V; HSA), Freund's complete and incomplete 
adjuvants (FCA, FIA), anhydrous citric acid, o-phenylenediamine (OPD), goat 
! 
anti-rabbit immunoglobulin G (lgG) (whole molecule), rabbit anti-goat lgG 
(peroxidase labelled) were purchased from Sigma (St. Louis, MO, USA). j 
Tween 20，hydrogen peroxide (30%), ethyl acetate, sodium phosphate 
salts(Na2HPO4 and N a H 2 P O 4 ) , sodium chloride and sodium sulphate (all AR 
grade) were supplied by E. Merck (Darmstadt, Germany). Methanol (HPLC 
grade), sulphuric acid (H2SO4; 98%; AR grade) and hydrochloric acid (HCL; 
370/0; AR grade) were from Mallinckrodt (Paris, KN, USA). Carboxymethyloxime 
hemihydrochloride (CMO) and pyridine were from Aldrich (Milwaukee, Wl, 丨 
巧' !. 
USA). All steroids were kindly provided by Dr. Francis P.W. Tang ofthe Racing i 
Laboratory, The Royal Hong Kong Jockey Club (RHKJC). ELISA microtitre j 
plates (Microtest III) were from Falcon (Oxnard, CA, USA). Dialysis tubings (cut 
off: mol_ wt. > 12,000) were also supplied by Sigma. 
I 
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2.2.2. Preparation of 6-B-hydroxycortisol-21-acetate-3-carboxylmethyloxime 
protein conjugates 
These conjugates were synthesized using a modified method of Jondorf 
i 
(1977). As outlined in Fig 2.1，a carboxyl containing group was first attached 
i 
to the steroid molecule. The carboxyl group was then linked to the terminal 
amino group on the protein carrier. 6-B-OHC-21-acetate (0.5 mmol, 0.21 g) and 
carboxymethyloxime hemihydrochloride (0.5 mmol, 0.058 g) were dissolved in 
pyridine (5 ml). The mixture was then stirred overnight in darkness at 5 °C. 
Pyridine was then removed by evaporating under nitrogen. Distilled water (10 
ml) was added to the mixture, followed by extraction with ethyl acetate (50 ml). 
The organic extract was washed twice with 10 ml saturated brine. After 
washing, the organic extract was then dried with anhydrous sodium sulphate 
and concentrated to give a final yellow powder of 6-B-0HC-21-acetate-3(0-
carboxylmethyl)oxime (6-B-OHC-21-Ac-3-CMO). 丨 
6-B-OHC-21-acetate-3(0-carboxymethyl)oxime (1 mmol, 150 mg) and 
I 
tri-n-butylamine (1 mmol, 200 pl) were dissolved in 10ml ofdioxane in a dried 
tube. The mixture was then allowed to cool to 10 °C, followed by addition 100 
pl of isobutyl chlorformate with stirring at 4 °C for 30min. BSA (600 mg) in 
distilled water (60 ml) was then added dropwise over one hour with continuous 
stirring at 4 °C. After stirring for 24 hours, the mixture was dialysed against 
a： 
distilled water (5 L) for 24 hours with five changes of water. The dialysate was | 
p' 
I 
44 j | 
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6-P-OHC-21-Acetate 6-P-OHC-21-Acetate 3-O-carboxymethyl oxime 
(6-P-OHC-21-Ac-3-CMO) 
Part I: Synthesis of 6- P-OHC-21 - Acetate 3-O-carboxymethyl oxime 
Part n : Linking of 6-P_OHC-21-Ac-CMO to protein carriers 
CHoOAc 
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then lyophilized and stored desiccated below 0 °C. Other steroid-protein 
conjugates with OVA and HSA were also synthesized using the same method. 
All steroid-protein conjugates (1 mg/mL), 6-B-OHC-21-Ac-3CMO (0.1 mg/ml) 
and protein carriers (1 mg/mL) were scanned for their ultraviolet (UV) 
absorption spectra (200-300 nm) to determining their epitope density (Erlanger 
etaL’ 1957). 
2.2.3. Immunization of rabbits with 6-R-hydroxycortisol bovine serum 
albumin conjugate (6-S-OHC-BSA) 
6-S-OHC-BSA (15 mg) was dissolved in normal saline (0.85 % w/v, 7.5 
mL) and Freund's complete adjuvant (FCA) (7.5 mL) was added [Freund's 
incomplete adjuvant (FIA) was used for the second and subsequent 
immunization]. The water-oil mixture was then emulsified by two syringes ： 
connected with a double-hub needle (Herbert, 1973). Emulsification took place i| 
when the mixture was passed rapidly back and forth between the syringes a f 
I 
: 
few dozen times. Emulsification was judged to be successful when a drop | 
allowed to fall onto the surface of a beaker of water, remained as a discrete 
globule. 
Four male New Zealand White rabbits (2 - 2.5 kg) were housed in 
individual metal cages and allowed free access to food and water. A 12 hours 
light and dark cycle was maintained in the holding area. Each rabbit was 
圓 ii-it i:,. 46 . . 、 i. t I II 
• • ^ 
immunized with a total of 3 mL (1 mg/ml) drug-protein conjugate emulsion: 1 
mL intramuscularly to each hind leg，and 1 mL in divided dosed to four 
I 
subcutaneous sites on the back (0.25 mL for each site). Injections were 
repeated at monthly interval. Blood samples from each rabbit prior to 
V 
immunization and on day 14 after each injection were obtained from the ear 
vein. Blood was allowed to clot overnight at room temperature. Serum was 
obtained by centrifugation (3,000 r.p.m. for 10 minutes). The serum was stored 
as 1 mL aliquot at -20 °C. 
2.2.4. Enzyme-linked immunosorbent assay (ELISA) 
The specific anti-6-S-hydroxycortisol antibody activity was determined 
by using an indirect enzyme-linked immunosorbent assay (ELISA) method. As 
shown in Figure 2.2，microtitre plates (Falcon Microtest III) were coated with 6-
B-hydroxycortisol-ovalbumin (6-B-OHC-OVA) or OVA (0.01mg/mL, 125 | 
^j|/well) in coating buffer (0.05M phosphate buffed, pH 7.2) at 4。C overnight in 
a humidified chamber. On the next day, the plates were washed 3 times with 
PBS-Tween (0.15M phosphate buffed, pH 7.2, contains 0.9% w/v sodium 
chloride and 0.05% v/v Tween 20, freshly prepared) and shaken dry. All 
subsequent washes were performed in the same manner with PBS-Tween. 
PBS-Tween was also used as the dilulant for all sera and anti-sera. The plates j 
were then incubated at room temperature in a humidified chamber for one hour 
with each of the following reagents, with washing between each step: test sera i 
47 I； 
• 
i : L 
！ 
Coat plates with 0.01 mg/ml 6-B-OHC-OVA/OVA || 
in coating buffer: 125 pL/well 
• 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with test samples for 1 hour at room temperture 
• 
, 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with goat anti-rabbit lgG (1:1000), 100 ML/well 
for 1 hour aWoom temperture 1 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with rabbit anti-goat lgG peroxidase labelled 
(1:1000)，100 pL/well for 1 hour at room temperture 1 
• 
Wash 3 times with PBS-Tween and shake dry : 
I • 'i'i 
:!S,: 
> ! . 
incubate with OPD substrate solution: 100 pL/well for I 
20 mins. at room temperture | • i stop reaction by adding 25 % H2SO4 : 50 ML/well J 
I 
|4I 
Read absorbance at 490 nm | 
Firure 2.2. Flow diagram of ELISA procedures for the detection || 





(100 ^iL/well) at the initial dilution of 1:100 serially diluted (5-fold) down 
columns; goat anti-rabbit lgG (100 pL7well, 1:1000 dilution); rabbit anti-goat lgG 
(peroxidase labelled) (100 fjL/well，1:1000 dilution); substrate solution (100 
pL7well, containing 0.1% v/v hydrogen peroxide and 400 pg/mL OPD in 0.15M 
citrate-phosphate buffer, pH 5.0). The reaction was quenched'by adding 25% 
j,i 
v/v H2SO4 (50 ML/well) after 20 minutes. Absorbance at 490 nm of each well j 
was read by a dual wavelength reference set at 570 nm. 
Antibody titre was calculated as the dilution of antiserum giving an 
absorbance of 0.5. Anti-6-(l-hydroxycortisol lgG activity was defined as the 
antibody titre following coating of plate with 6-S-OHC-OVA, when no activity 
was detected against OVA alone. |： 
To determine the intra-assay coefficient of variation, rabbit antiserum 
(100 ^JL，1:50,000 dilution) was added to each well of a 6-S-OHC-OVA coated 
microtitre plate. The plate was then subjected to the ELISA procedures as 
described. Intra-assay coefficient was calculated as the coefficient of variation | 
(standard derivation/mean x 100%) between 96 wells on the plate. Four 96-well | 
plates were set up with the same treatment as described. The interassay 





2.2.5. Hapten inhibition analysis 
The specificity of the rabbit anti-6-S-hydroxycortisol antibodies was 
determined by hapten inhibition studies (Yeung et al., 1985). The cross 
reactivity of the antiserum with different carrier proteins and structurally related 
steroids was evaluated. The antiserum was preincubated with carrier proteins, 
the steroid-protein conjugates and other steroids before the ELISA was 
performed as previously described. Briefly, serial dilutions of the potential |： 
inhibitors were prepared (0.2 -100 pg/mL) in PBS-Tween. Aliquots (150 \jL) of 
each inhibitor were mixed with rabbit antiserum (150 pL, 1:50,000 dilution) and 
I： i! 
I: 
incubated at 4 °C overnight. The supernatants were then used in the ELISA for 
detecting the specific anti-6-R-hydroxycortisol lgG activity. The inhibitors used 
in the study included steroid-protein conjugates [6-R-hydroxycortisol-bovine ( 
serum albumin(6-R-OHC-BSA), 6-R-hydroxycortisol-ovalbumin(6-B-OHC-OVA) 
and 6-(i-hydroxycortisol-hunnan serum albumin(6-R-OHC-HSA)], the | . 
unconjugated carrier proteins (BSA, OVA and HSA) and 34 structurally “ 
similar/unrelated steroids (Table 2.1). A methanol control was used in the \.. 
hapten inhibition study because the steroids were dissolved in methanol initially 
as stock solutions. 
；!!•. I! 












Table 2.1. Steroids used in inhibition ELISA analysis 
1. 5a-Androstane-3R, 17a-diol 18. Epitestosterone 
2. 5a-Androstane-3B, 17S-diol 19. a-Estradiol 
3. Androstenediol 20. Estradiol 
4. Androstenedione 21. Estratriol | 
5. Androsterone 22. 6-S-Hydroxycortisol 
1 ：丨 
6. Betamethasone 23. 6-S-Hydroxycortisone 
7. Boldenone 24. Hydrocortisone 
‘ 
8. Corticosterone 25. Methylandrostanolone 
9. Cortisone 26. Methylprednisolone [ 
10. 11-Dehydroepiandrosterone 27. Methyltestosterone 
11. Dehydroepiandrosterone 28. Nandrolone 
12. Dexamethasone 29. Prednisolone 
13. Dihydroandrosterone 30. Prednisone | 
I 
14. 5a-Dihydrocortisol 31. Progesterone | 
15. 5B-Dihydrocortisol 32. Stanozolol 
16. 5a-Dihydrotestosterone 33. Testosterone I 
f 









2.2.6. Calculation of cross reactivity 
_ ,1 
The cross reactivity of each inhibitor relative to 6-fi-hydroxycortisol was | 
determined by establishing their inhibition curves from the data obtained in ； 
inhibition ELISA. For example, the inhibition curves for steroid X and steroid | 
Y could be set up as follows: 
•： 
I 1 丨 
\、％、 j 
_ _ ^ 5 0 % inhibition concentration 
Ar^^^“ 
log [ Concentration ] | 
^ 1 
The 50% inhibition concentrations (IC50) of X and Y were the ！ 
concentrations that inhibited half of the ELISA reaction. The cross reactivity of f' 
L 
the anti-X-antiserum to steroid Y could be expressed in cross reactive ^ 
I 
percentage (CR%), described as follows: t 
IC50OfX 
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for determination of urinary 6-B-OHC in human and animal 
model i ir 
2.2.7.1. Quantification of 6-R-OHC in human urine samples by ELISA j 
Four healthy male volunteers, age between 24 to 37 years, were 
investigated in this study. All were non-smokers and none had taken any drugs 
for at least a week prior to and during the study. All volunteers were informed 
of the aim of the study and gave their written consent. Subjects were 
specifically asked not to change their life style, including food consumption, 
! 
during the course of the study. 24 hour (09:00 - 09:00) urine collections were 
made on the day (day 1) before drug administration. Rifampicin was taken |r 
orally by subjects, 600 mg/day for 4 days. After 4 days of rifampicin treatment, ! 
24 hour urine collections were taken on day 5. A portion (10 ml) of the total 24 | 
hour urine was stored without preservative in polystyrene tubes at -20 °C until i 
assayed. The urine samples (15 pl), before (day 1 sample) and after rifampicin 
I 
treatment (day 5 sample), were transferred to a glass test tube and mixed with | 
I 
135 H^ PBS-Tween buffer rabbit antiserum R1-2B (150 pl，1:50,000 dilution) I 
was added to each tube, which were sealed and incubated at 4 °C overnight. 1 
On the next day, aliquots (100 MO ofthe supernatant were assayed by inhibition | 
ELISA as described previously (Section 2.2.5). The concentration of 6-S-OHC ‘ 
l'i 
in each urine sample was determined by matching the absorbance to the | 
I 53 I 
. 
corresponding concentration on the inhibition standard curve of 6-B-OHC 
一 一 ― ― I 
I 
‘ 1丨 
2.2.7.2. Quantification of 6-R-OHC in rat urine | 
! 
Male Sprague-Dawley rats (300-350 g), were housed in individual ! 
metabolic cages with free access to food and water during the course of study. | 
Urine samples (24 hours) were collected from each rat on the day before 
administration (day 1) of drugs. The drugs used were : rifampicin (80 
mg/kg/day), cimetidine (80 mg/kg/day), nifedipine (50 mg/kg/day) and | 
ketoconazole (30 mg/kg/day). After 4 days a final 24 hour urine sample l| 
collection was collected on day 5. The urine samples were collected without | 
preservative and stored in polystyrene tubes at -20 °C until analysed. The | 
； I 
urinary 6-S-OHC level in rat urine was determined by the same protocol of 
inhibition ELISA as described in human urine study (Section 2.2.7.1). 
l： 
I 
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2.3.1. Characterization of the steroid-protein conjugates 
In UV spectra analysis, the maximum absorption (Amax) of 6-li-OHC-21-
Ac-3CM0 (mol. wt: 493; 0.1 mg/ml) at 250 nm was 0.24. Hence, the molar 




no. of mole / litre J 
and equal to 6670. Similarly, the X^ ax of BSA (mol.wt: 68000; 1 mg/mL) | 
occurred at 250 nm and 1 was found to be 19380. 6-li-OHC-BSA (0.01 mg/mL) | 
exhibited absorbance of 1.09 and 0.3 at wavelength 220 nm and 250 nm 
respectively and BSA (0.01 mg/mL) also showed an absorbance of 0.06 at 250 | 
nm. Hence the difference (0.3-0.06 = 0.24) between the absorbance of 6-Q>-
'•• ； I 
OHC-BSA and BSA at this wavelength represents the contribution of 6-S-OHC- | 
!i; 
21-Ac-3-CMO to the absorbance. Based on the assumption that I of 6-R-OHC- | 
21-Ac-3-CMO will remain the same after conjugation to the protein (Erlanger 
et al” 1957), the 6-R-OHC-21-Ac-3-CMO residue is 0.24/0.67 x 10^ = 3.6 x 10'^  ! 
mol/L. Under the same assumption the concentration of BSA in 6-S-OHC-BSA ^ 
would be 1.328 x 10 ® mol/L Consequently, the amount of 6-B-OHC-21-Ac-3- t 
I 
CMO residues attached to each mole of 6-B-OHC-BSA (epitope density) is 3.6 ;: 
X 10-5/1.328 X 10_6 = 27. Similarly, the epitope densities of 6-B-OHC-OVA and | 
55 I I: i^ 
6-B-OHC-HSA are 15.5 and 28 respectively. 
!：• 
2.3.2. Anti-6-R-OHC lgG activity in immunized rabbits' sera 
As shown in Fig. 2.3, anti-sera from all four rabbits immunized with 6-S- [ 
丨 
OHC-BSA showed specific anti-6-(l-OHC lgG activity over the course of 
immunization. There was no further increase in the antibody titre after the 2nd 
booster injection. The anti-serum of rabbit no.1 sampled on day 14 after 2nd 
booster injection showed the highest antibody titre (1:500,000 dilution), it was | 
selected for further inhibition experiments under the code R1-2B. j 
I [ 
2.3.3. Characterization of rabbit antiserum (R1-2B) | 
丨: 
fi 
Inhibition ELISA studies showed that the specific anti-6-S-OHC lgG .： 
丨  
activity of R1-2B was inhibited after preincubation with 6-R-OHC-BSA, 6-R-
[丨 
OHC-OVA and 6-R-OHC-HSA, but not with the respective carrier proteins | 
I 
(BSA, OVA and HSA)(Fig 2.4). Hapten inhibition studies showed that four 1 
I 
steroids inhibited the antibody activity (Fig. 2.5); they are 6-R-OHC-Ac-3-CMO, t 
6-B-OHC-21-Ac, 6-a-OHC & 6-B-OHC. Table 2.2 shows the cross reactivities | 
of these steroids with respect to the antibody. The antibody can recognize 6-R- |i 
OHC within the concentration range of 0.5 ng to 10 pg/mL (Fig. 2.5 and P 
Fig.2.6). The stereo-specific discrimination between 6-B-OHC and its | 
stereoisomer 6-a-OHC is weak. Furthermore, three structurally related steroids |； 
I 
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Figure 2.3a. Time course of appearance of anti-6-R-OHC antibody 
(lgG) in the rabbit antiserum No1. Anti-6-li-OHC lgG activity was 
measured by ELISA.(n=6) 丨丨, 
i 
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Figure 2.3b. Time course of appearance of anti-6-B-OHC antibody 
(lgG) in the rabbit antiserum no.2. Anti-6-(i-OHC lgG activity was | 
measured by ELISA. (n=6) i 
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Figure 2.3c. Time course of appearance of anti-6-S-OHC antibody | 
(lgG) in the rabbit antiserum No.3. Anti-6-R-OHC lgG activity was 
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Figure 2.3d. Time course of appearance of anti-6-(J-OHC antibody 1 
(lgG) in the rabbit antiserum No.4. Anti-6-R-OHC lgG activity was 
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Figure 2.4. Inhibition ELISA of anti-6-R-OHC lgG activity after 
preincubation of rabbit antiseum R1-2B (obtained on day 14th after 
2nd booster of 6-R-OHC-BSA immunization; 1:50000 serum dilution) 
with various 6-B-OHC-protein conjugates (6-R-OHC-BSA,6-S-OHC-
OVA and 6-R-OHC-HSA) and carrier protein (BSA). Other carrier 『 
proteins (OVA & HSA) showing inhibition curves similar to that of BSA | 
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Figure 2.5. Inhibition ELISA of anti-6-R-OHC lgG activity after 
preincubation of rabbit antiserum, R1-2B (obtained on day 14th 
after 2nd booster of 6-B-OHC-BSA immunization; 1:50,000 serum 
dilution) with various concentration of three steroids. The inhibition 
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Figure 2.6. Inhibition ELISA of anti-6-R-OHC lgG activity after 
preincubation of rabbit antiserum, R1-2B (obtained on day 14th after 
2nd booster of 6-B-OHC-BSA immunization; 1:50000 serum dilution) 
with various concentration of three steroids. The inhibition standard 
curve of 6-S-OHC is also presented in this figure, (n=6) 
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Table 2.2 Cross-reaction of rabbit polyclonal anti-serum R1-2B (obtained 
by 6-li-OHC-BSA immunization) to various steroids. 
Cross Reactively In % 









other structurally similar steroids: | 
Cortisone 1 \ 
Hydrocortisone 1.6 \ 





,1 • . • 
also showed slight inhibition ofthe antibody (Fig. 2.6), but the cross reactivities 
were less than 5% (Table 2.2). The structure of five strongly inhibiting steroids 
are shown on Fig.2.7. Other steroids tested had their IC50 values well outside 
the range of concentration investigated. 
2.3.4. Quantification of 6-S-OHC in human urine samples by ELISA 
using antisera R1-2B 
As shown in Fig. 2.8, before rifampicin treatment, the total concentration 、 
1 
of urinary 6-B-OHC collected in 24 hours was 370 土 105 pg (on day 1 control . 
I.I 
sample). After 4 days treatment with rifampicin, the total concentration of | 
h jfj 
urinary 6-li-OHC in 24 hours production was significantly increased to 1350 土 ti 
201 pg on the day 4 sample, which was 4 fold greater than the control ! 
I 
(P^0.001). 、 I 
1 i *»< 
？ 
2.3.5. Quantification of 6-R-OHC in rat urine samples by ELISA using | 
polyclonal antisera R1-2B | 
_ 
Rat urinary 6-R-OHC concentration after various drug administration 
were detected by the antisera R1-2B based ELISA method. As shown in Fig. 
2.9, a significant increase in the production of 24 hours urinary 6-S-OHC 
concentration was observed after rifampicin administration, from 30 土 9 pg on 
day 1 control to 3500 土 800 M9 on the day 5 sample (P^0.001). In the other 
studies, total 24 hours urinary 6-(i-OHC concentration were determined after 
cimetidine, ketoconazole or nifedipine administration. Fig. 2.10 showed that a 
65 
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Fig 2.7 The structures of five strongly inhibiting steroids with rabbit antiserum 
Rl -2B and monoclonal antibody 19F, in inhibition ELISA analysis. 
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Figure 2.8 The total amount of urinary 6-R-hydroxycortisol (24 hours) in 
human urine before and after rifampicin administration (600 mg/day for 
4 days). The 6-B-hydroxycortisol was determined by polyclonal 
antiserum R1-2B based hapten inhibition ELISA. Results are presented 
as the mean (SD). (**P<0.001 by Student's paired t-test, n=6 ) 
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Figure 2.9 The total amount of urinary 6-R-hydroxycortisol (24 
hours) in the rats before and after rifampicin administration ：^ 
(80mg/kg/day for 4 days). The 6-R-hydroxycortisol was determined by 
polyclonal antiserum R1-2B based hapten inhibition ELISA. Results 
are presented as the mean (SD). ( **P<0.001 by Student's paired t-
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Figure 2.10 The total amount of urinary 6-S-hydroxycortisol (24 hours) 
in the rats before and after ketoconazole administration (30mg/kg/day ， 
for 4 days). The 6-B-hydroxycortisol was determined by polyclonal 
antiserum R1-2B based hapten inhibition ELISA. Results are .：^ 
presented as the mean (SD). ( **P<0.001 by Student's paired t-test, '' 
n=6) 
69 




一 | : : 
.:'t' ‘ \ ;i: 、 ：j.h.. 
i ! f _ : • 
100n 丨 
I I Before cimetidine treatment [ 
I 1 After cimetidine treatment | 
^ I 
i • i 
5 10- T • 丨 
CM 
C 「 
• — ',! 
D) t I 0) 
t 1 _ f 0 • _ icic i\ 
> ； 
1 r _ I ~~ ^ " || r n 
i 1 丨 
o . o o i J 1 11 
’fS 
Figure 2.11. The total amount of urinary 6-B-hydroxycortisol (24 hours) 1 
in the rats before and after cimetidine administration (80mg/kg/day for 'j^  
4 days). The 6-B-hydroxycortisol was determined by polyclonal 震 
antiserum R1-2B based hapten inhibition ELISA. Results are 
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Figure 2.12 The total amount of urinary 6-R-hydroxycortisol (24 | 
hours) in the rats before and after nifedipine administration i：^ 
(50mg/kg/day for 4 days). The 6-S-hydroxycortisol was determined f| 
by polyclonal antiserum R1-2B based hapten inhibition ELISA. |-. 
Results are presented as the mean (SD). (** p<0.001 by Student's i| 






reduction in 6-B-OHC concentration was observed after the administration of 
ketoconazole, from 18 土 11 l^g on the day 1 control sample to 0.049 士 0.021 pg ,;丨 !(•|:, 
on day 5 sample (P^0.001). Cimetidine and nifedipine, also reduced the total '||, 
'('‘ 
,i 
24 hours urinary 6-B-OHC concentration (Fig. 2.11 and Fig. 2.12 respectively). | 
• I 
gi；； 
2.3.6. Intra-assay and inter-assay coefficients '、 
^ 
I .• 
The intra-assay and inter-assay coefficients of variation of the ELISA 
« 




















2.4. Discussion ： 
Ji i 1 
In this study, 6-li-OHC was conjugated to a protein carrier (BSA, OVA | 
1 
I 
and HSA) by substitution of a CMO group at the C3 position, this provided a 
丨丨丨 
terminal carboxylic acid group which allowed the formation of a peptide bond ii}! 
I I 
with the terminal amino group on the lysine residues on the protein carriers. j|>, 
I if 
The immunization of 6-B-OHC-BSA in rabbits gave rise to specific anti-6-S- j| 
OHC antibodies detected by ELISA. The specificity of the antibody was 丨丨 
confirmed, based on the criteria as previously described (Yeung et al., 1985) j 
：(1) The antibody reacts with the immobilized 6-R-OHC-OVA conjugate, but not || 
I,丨丨. 
〜 to the immobilized protein carrier OVA. (2) The antibody activity was inhibited ;i, li i il| 
by the preincubation of the antiserum with steroid-protein conjugates (6-R- /'' 
sf ii 
OHC-BSA, 6-(i-OHC-OVA and 6-R-OHC-HSA), but not with the same ( 
‘ 
unconjugated protein carriers. (3) The reaction was inhibited by preincubation 
of the antiserum with 6-B-OHC alone, but not with other steroids. The antibody | 
•r 
also exhibited a very weak ability to differentiate the stereoisomer of 6-a-OHC. 
The detection limit ofthe antibodies to 6-R-OHC was as low as 1 ng/ml, 
such sensitivity was comparatively lower than those reported in previous 
studies using rabbit polyclonal antibodies on RIA [ 0.025 ng/ml (Kishida et al” 
1977) and 0.05 ng/ml (Park, 1978) ] and ELISA [ 0.01 ng/ml (Azzedine et al., 






II - Il, 
' the ability of the antibodies in recognizing 6-S-OHC was still within the range 
• ll 
of human daily urinary 6-li-OHC outputs in normal adult (100-400^)(Dumont | 
丨丨丨丨.丨 
et al” 1984; Ono et al” 1986; Nakamura and Yakata 1989; Chul 1995)，the |: 
,!';'' 
antibody R1-2B is sufficiently sensitive for accurate detection of 6-S-OHC in ； | 
:丨I 
l : i 
. . I 
urine. The specificity ofthe antibody was confirmed by hapten inhibition studies 
to be less than the acceptable 5% cross reactivity. 
1 
In human studies, the change in urinary concentration of 6-S-OHC was |[ 
1 
investigated using rifampicin (Ged et al” 1989)，a well known enzyme inducer, i, 
1： 
to volunteers. The total 24 hours urinary 6-S-OHC concentrations were | 
i^I 
increased from 370 士 105 pg (before rifampicin treatment, obtained from day | 
I' 
1 samples) to 1350 土 201 M9 (after rifampicin treatment, obtained from day 5 丨�| 
)» 
I i, 
samples) (Fig. 2.7) and these values were consistent with results obtained from | 丨  
previous studies using radioimmunoassay (Ohnhaus et al., 1989; Bammel et t 
a/.’ 1992). In the animal studies, rifampicin caused a significant enzyme j 
induction as indicated by the total 24 hours urinary 6-S-OHC production. | 
II 
Enzyme inhibitors were investigated in this study with ketoconazole being the 
most potent inhibitor (Fig. 2.10) followed by cimetidine (Fig. 2.11) and | 
I 
nifedipine (Fig. 2.12). These results confirmed the results from previous studies I 
J 
that these drugs can inhibit the CYP IIIA enzyme activities (Shinn et al., 1992; | 
.fi! 





In summary, an ELISA has been established to detect specific rabbit 
anti-6-R-OHC lgG antibodies. The cross reactivity and sensitivity of the 
antibodies R1-2B were confirmed by inhibition studies using 6-li-OHC 
conjugated proteins and other steroids. The ELISA method thus provided an 
alternative screening method for the detection of specific anti-6-S-OHC 
antibodies. The detection limit ofthe antibodies to 6-R-OHC in this method was 
found to be comparable to previous studies and within the suggested 
detectable range of 6-B-OHC level in rat and human urine. In addition, the 
antibody R1-2B raised in this studies was also found to be sufficiently sensitive 
and specific for the detection of the changes in 6-B-OHC level in human and 
rat urine. The ELISA method established in this study thus provided a sensitive 
and specific screening method for the detection of specific anti-6-S-OHC 
antibodies in the preparation of monoclonal antibodies. In addition, the 
polyclonal antibodies may be used as a reference standard to compare the 




Development of a Monoclonal Antibody-Based ELISA against 
6-&-hydroxycortisol (6-B-OHC) and its Applications 
3.1.1. Properties of monoclonal antibody 
In 1975，Kohler and Milstein developed a technique for the production 
of homogeneous antibody with defined and predictable properties, by somatic 
cell fusion (hybridization) between an antibody producing cell (normally B cell) 
and an immortal cancerous cell (normally myeloma). The hybrids or 
hybridomas is/are the only product ofthis fusion technique, which will retain the 
properties of their parent cells and secrete only one kind of antibody with its 
unique properties. The antibodies are generally homogenous in specificity, 
affinity and isotope, with each antibody being specific to a single antigen 
determinant of the defined antigen (mono specific); therefore this type of 
antibody is called a monoclonal antibody (MAb). MAbs are unique because all 
the antibodies produced in a single preparation can be identical and， 
theoretically be obtained in unlimited amount. These properties makes them 
favourites as universal standard reagents in immunoassays，providing 
standardization. Furthermore, due to their pre-defined specificity, monoclonal 
antibodies can avoid the problems of cross-reaction with other irrelevant 
antigens. 
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Monoclonal antibodies have been widely used, for examples in the 
development of immunoassays, diagnosis and detection of cancer, 
immunosuppression in organ transplantation and in plant pathology (Zola, 
1987). In future, the applications of such unique antibodies are expected to 
become more wide spread and popular. 
3.1.2. Monoclonal antibodies in immunoassays 
With their well-defined specificity and affinity, MAbs are useful in the 
establishment or refinement of particular immunoassays for haptens. With the 
possibility of an unlimited supply of antibody activity remain constant over a 
long period oftime, MAbs can be prepared as a worldwide reagent which make 
standardization of any immunoassays based on these antibodies become 
possible. 
Despite certain advantages that MAbs seem to have over conventional 
polyclonal antibodies, MAbs have not totally replaced polyclonal antibodies in 
immunoassay. This is because the monospecific property of MAbs may lead 
to low specificity and cross-reactivity with compounds related to the hapten 
(often broader than that of polyclonal antibodies). The affinity of MAbs is 
usually lower than that of polyclonal antibodies (Fantl and Wang, 1983; Al-
Dujaili et al” 1984; Olivier et al., 1992). These limitations of MAbs may 
contribute to problems with many monoclonal antibody-based immunoassays. 
To overcome these disadvantages, it is recommended that a large number of 
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particular MAbs is developed in each preparation, which can help in the 
selection of a suitable MAb with the appropriate analytical specificity and 
sensitivity (Olivier et a/.,1992). After the best MAbs are selected and the 
sensitivity of MAbs have been clarified, the antibodies will exhibit real 
advantages over polyclonal antibodies because they can offer an unlimited 
amount of worldwide standardized reagents. 
3.1.3. Production of monoclonal antibodies 
Based on the method by Kohler and Milstein established in 1975, with 
modifications, many of mouse monoclonal antibodies specific to various 
haptens and steroids have been developed. These include MAbs for 
cyclosporin (Quesniaux etal.，1987; Holt et al., 1991)，propranolol (Wang et 
a/.,1986), benzodiazepines (De Blas etal., 1985), testosterone (Kohen etal., 
1982; Fantl and Wang，1983)，progesterone (White etal” 1982)，estradiol (De 
Lauzon et a/.，1990) and 18-hydroxycortisol (Gomez et al” 1987; Hiroaki et a/., 
1994). After more than 10 years of refinement of the hybridization technique, 
the preparation of monoclonal antibodies has now become a standard and 
routine technique. Basically, there are three major determinants for the 
successful production of MAbs: the screening procedure for individual MAbs, 
immunization of animals, and the hybridization technique. These determinants 
can directly affect the MAbs produced in terms of specificity and sensitivity. 
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3.1.3.1. Screening assay for monoclonal antibodies 
Development of a suitable screening method is essential for the 
production of MAb. A reliable screening assay allows selection of the best 
responsive mice for hybridization, and also provides a screening test to study 
and characterise the antibodies secreted from the hybrids. Most of the 
hybridoma ceils will grow rapidly after fusion experiments and the antibodies 
are normally ready for screening within a few days. A reliable screening method 
should be fully established before hybridization is carried out. Otherwise, there 
is little time to set up or refine the screening method after that. 
An ideal screening assay for MAbs should identify the antibodies in a 
simple, rapid and inexpensive manner for a large number of samples each time 
(Zola, 1987). Basically, any immunoassay systems which are based on the 
antigen-antibody reaction could be used. In this study, an enzyme linked 
immunosorbent assay (ELISA) is used as a screening assay for desired MAbs, 
and which is adapted from existing screening methods using rabbit antiserum 
(Chapter 2). 
3.1.3.2. Procedures for monoclonal antibodies production 
The immunization procedures for monoclonal antibodies production are 
similar to those used in conventional polyclonal antibody production. For 
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immunization, 8-12 weeks old, non-stressed mice of either sex were found to 
yield the highest levels of both total lgG and the specific antibody (Hu et al., 
1990). The immunogenicity of the immunogen is also important for specific 
antibody production. For small hapten molecules, conjugation with a carrier 
protein enables the increase in the immunogenicity. Moreover, the choice of 
attachment site of the hapten to the carrier protein can influence the specificity 
of MAbs (Oilver et al。1992). It is suggested that if biotransformation can occur 
at certain sites which are outside the epitopic zone of the conjugates; all the 
metabolites ofthe hapten with the unmodified rigid skeleton can be recognized 
by the MAbs. (Quesniaux et a/.，1987). Thus, before the preparation of a 
hapten-carrier conjugate for immunization, the metabolic pathway ofthe hapten 
should be clearly established and it is suggested that the coupling sites should 
be metabolically inert. 
A good immunization technique should be able to maintain an optimal 
concentration of antigens for a long time. This can be achieved by giving 
repeated dosages of immunogen at regular time intervals, between 4-6 weeks 
(Hu and Kitagawa 1990). For hybridoma production, a final booster of a similar 
or even higher dose of immunogen, without adjuvant, should be administered 
3 or 4 days before the fusion experiments are preformed (Stahli et al., 1980). 
This final booster can induce a strong antibody response and increase the 
number of antigen specific antibody secreting cells as fusion partner. 
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3.1.3.3. Hybridization for monoclonal antibodies production 
Hybridization allows two different types of cells to be fused 
together, with their genetic properties retained and functional in the fusion 
products (hybrid/hybridoma). Some variations in hybridization techniques have 
evolved over the past two decades, although most of them are based on the 
techniques of either Galfre et al.，(1977) or Gefter et al” (1977). The most 
important modifications in these hybridization techniques include the choice of 
fusion partner, fusion agent and the hybrid selection system. 
3.1.3.3.1. Fusion partners for mouse monoclonal antibodies production 
Myeloma cell lines are often used as the fusion partner in hybridization 
for monoclonal antibodies production. The main advantage of these cell lines 
is that they can offer all the genetic requirements necessary for the hybrid to 
survive and secrete antibodies permanently. Many myeloma cell lines are 
available, each having their own characteristics and genetic features. It is 
therefore necessary to consider their properties before selecting the most 
suitable cell line for hybridoma preparation. It is suggested that myeloma cells 
should fulfill the following conditions (Peters, 1991): 
1) They do not produce their own antibody, so that only one type of 
antibody is produced. 
i 
81 
2) They must possess an enzyme defect, which affects their survival 
after the fusion. This enables the removal of the unwanted hybridoma 
or nonfused myeloma cells, when an effective hybridoma selection 
system is employed. 
3) They should have good fusion properties, so that the number of 
hybridomas produced is as large as possible. 
4) They should have a high MAb synthesis rate in the hybridoma. This is 
the main reason why myeloma lines are commonly used in the 
hybridoma. 
Table 3.1 lists some of the myeloma cells which are commonly used for 
hybridoma preparation. The other fusion partner needed in hybridization 
technique is the isolated B-cell which can be obtained from immunized animals. 
The cell contains the necessary genetic materials which allow the fused 
hybridoma to secrete the desired antibody. Due to the practical difficulties in 
purification and selection of the most suitable antibody-secreting cells, fusion 
experiments are normally done with a mixed population of isolated antibody 
secreting cells from a lymphoid organ (generally the spleen) of a successful 
immunized host. 
3.1.3.3.2 Fusion agents 
The type of fusion agent has played an important role in the success of 
hybridoma production. This is because a good fusion agent can enhance the 
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Table 3.1. Commonly used myeloma cell lines for hybridoma production 
(Zola, 1987). 
Cell line Derived from Chains Secreting 
expressed 
Mouse lines: 
P3-X63Ag8 P3K y1,/c lgGi 
X63Ag8.653 P3-X63Ag8 None No 
Sp2/0-Ag14 P3-X63Ag8 x BALB/c None No 
F0 Sp2/0-Ag14 None No 
NSI/1-Ag4-1 P3-X63Ag8 Kappa No 
NSO/1 NSI/1-Ag4-1 None No 
FOX-NY NSI/1-Ag4-1 Kappa No 
Rat lines: 
Y3-Ag1.2.3 Y3 Kappa No 
YB2/0 YB2/3HL None No 
IR983F LOU/c rats None No 
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frequency of fusions between isolated antibody secreting cells and myeloma 
cells, thereby increasing the chance of obtaining successful and desirable 
hybridomas. In the first model reported by Kohler and Milstein (1975), success 
was obtained with an inactivated sendai virus as a fusogen. However, this type 
of fusogen is now almost entirely replaced by polyethylene glycol (PEG) 
(Pontecorvo, 1975) and PEG is still the most commonly used fusogen in any 
kind of hybridization technique. 
A number ofvariations in PEG fusion experiments have evolved overthe 
past decade. The concentration, purity, pH and duration of exposure of PEG 
are important variables. A concentration of PEG under 30% was insufficient at 
inducing cell fusion, while concentration of PEG over 50% may cause toxicity 
and the optimal concentration of PEG was therefore found to be 50% (Galfre 
and Milstein, 1981). The pH of PEG solution also has an effect on the fusion 
frequency (Sharon et al., 1980). It was found that maximal numbers of 
hybridoma were obtained within pH range of 8.0-8.2. The fusion frequency was 
also found to be increased with longer exposure to the PEG solution. However, 
over exposure to PEG may lead to toxicity and cell death. A high concentration 
(50%) of PEG with a short duration (1 min) of exposure has been widely 
accepted as the most suitable conditions for the production of hybridoma 
(Lane, 1985). 
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3.1.3.4. Hybrid selective system 
After fusion, there are normally four different cell populations present in 
the culture; they are nonfused myeloma cells, nonfused B-cells, unwanted 
hybridoma and the desired hybridoma. The nonfused B-cells will die off in a 
short time and will not cause any interference to future work. The wrong 
hybridomas, produced from the nonsense fusions between two B-cells with a 
myeloma cell, two myeloma cells with a B-cell, two B-cells with each other, two 
myeloma cells together, are irregular products, and will die off in a short time. 
The correct hybridomas, normally with low frequency (hybridoma frequency) of 
10^, are the desired population and must be grown. However, there are a large 
number of nonfused myeloma cells which remain in culture capable of 
continuous proliferation after the fusion. They would overgrow the desired 
hybridoma within a short time. Therefore, a suitable hybridoma selective 
system is used to eliminate the nonfused myeloma cells after fusion. The most 
commonly used selective system is based on the model by Littlefield (1964) 
(Fig. 3.1) in which HAT medium is used. Aminopterin (A in HAT) can block the 
main metabolic pathway for nucleic acids, whereas hypoxanthine and 
thymidine (H and T in HAT) can still support the remaining pathway for nucleic 
acid synthesis, which is known as the "salvage pathway" and thus normal cells 
can still continue to grow. Myeloma cells with enzyme defects in the salvage 
pathway cannot synthesis nucleic acid and hence do not survive in HAT 
medium because both metabolic pathways are blocked. Myeloma cells with the 
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Figure 3.1. The HAT system in hybridoma production (Littlefield, 
1964). See text for explanation. 




(HGPRT) are the most commonly used fusion partner for this selective system. 
It is suggested that genetic defects may arise as a result of mutations 
in cell cultures. Enzyme defective myeloma cells have occasionally been found 
to become mutant and grow in HAT medium. To prevent this, introduction of 
6-thioguanine or 8-azaguanine (Evans and Vijayalaxmi, 1981) into the culture 
will kill off all cells with an intact uptake pathway. A cell in which the uptake 
pathway is defective will be able to survive in such conditions, and will be able 
to proliferate further. 
3.1.3.5. Monoclonal antibodies against 6-li-OHC 
Following the development of a specific polyclonal antibody based 
ELISA for detection of specific anti-6-R-OHC lgG and quantification of urinary 
6-S-hydroxycortisol level in human and animal models (chapter 2)，experiments 
to develop a mouse anti-6-B-hydroxycortisol monoclonal antibody were 
undertaken. It was hoped that the monoclonal antibody will confer advantages 
over the existing polyclonal antibody (R1-2B) in terms of their specificity and 
sensitivity. The experiment also investigated whether the monoclonal antibody 
can discriminate the two stereoisomer, 6-a-OHC and 6-S-OHC. 
The protocol for developing MAbs against 6-S-OHC has three parts: (a) 
monoclonal smtibody production, (b) antibodies characterization and (c) the 
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determination of urinary 6-R-OHC in human and animal models. An ELISA 
similar to that described in Chapter 2，was used for the development of a 
suitable screening assay for specific anti"6-ft-OHC antibodies which is essential 
for the subsequent steps in monoclonal antibody preparation. After the 
monoclonal antibodies are developed, they are subjected to characterization 
for their specificity and sensitivity to 6-fi-OHC before any further uses of these 
antibodies are made. Suitable monoclonal antibodies are then used to measure 
the quantitative changes of urinary 6-(l-OHC in animal and human urine . Both 
of these models have been treated with a well known enzyme inducer 
(rifampicin) and enzyme inhibitors (cimetidine, nifedipine and ketoconazole). 
The results are finally validated by comparism with results obtained from 





3.2 Materials and methods 
3.2.1 Reagents and apparatus 
Dulbecco's Modified Eagle's medium (high glucose; DME), Dulbecco's 
phosphate buffered saline (D-PBS), fetal bovine serum (FBS), trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) solution, penicillinstreptomycin, 
fungizone, 8-azaguanine, sodium bicarbonate powder (NaHCO3, tissue culture 
( 
grade) and trypan blue solution (0.4%) were purchased from Gibco 
Laboratories (Grand Island, NY, USA). HAT supplement, HT supplement, 
polyethylene glycol (mol. wt. 1,300-1,600; PEG), red blood cell lysing buffer, 
dimethyl sulfoxide (DMSO) and L-glutamine (tissue culture tested) powderwere 
supplied by Sigma (St. Louis, MO, USA). o-Phenylenediamine (OPD), 
anhydrous citric acid, goat anti-mouse Immunoglobulin G (lgG) (peroxidase 
labelled), Freund's complete and incomplete adjuvants (FCA, FIA), acetyl 
chloride, bovine serum albumin (fraction V; BSA), ovalbumin (grade V; OVA) 
and human serum albumin (fraction V; HSA) were also from Sigma. Tween 20， ‘ 
hydrogen peroxide (30%), phosphate salts (Na2HPO4 NaH2PO4) and sodium 
chloride (all AR grade) were from E. Merck (Darmstadt, Germany). Methanol 
(HPLC grade), sulphuric acid (H2SO4； 98%; AR grade), hydrochloric acid (HCL; 
370/0； AR grade) and diethyl ether (AR grade) were supplied by Mallinckrodt 
(Paris, KN, USA). All steroids used in the experiments were generously 
provided by Dr. Francis P.W. Tang of the Racing Laboratory, the Royal Hong 
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Kong Jockey Club (RHKJC). All tissue culture wares were manufactured by 
Nunc (Rockilde, Denmark). ELISA microtitre plates (Microtest III) were 
purchased from Falcon (Oxnard, CA, USA). 
3.2.2 Immunization of mice with 6-R-hydroxycortisol-conjugated proteins 
Inbred male C57 mice (20-25 g) were supplied by the University Animal 
House and allowed free access to food and water. A 12 hours dark and light 
cycle was maintained throughout the holding area. Totally, a group often mice 
was used for the experiment. Each mouse, received an intraperitoneal injection 
of 6-R-OHC-protein conjugate (100 pg, 0.3 mL of the emulsion). Each 6各 
OHC-protein conjugate (1.4 mg) was mixed with physiological saline (0.85% 
w/v, 2 mL) and emulsified with Freund's adjuvant (2 mL) (complete adjuvant for 
initial immunization and incomplete adjuvant for other booster doses) as 
previously described (Chapter 2). Similar booster doses prepared with FIA 
were given for the following three months at monthly intervals. Mice which were 
found to be positively immunized by ELISA, were given daily doses of 6-Q>-
OHC-protein conjugates (200 M9 in 0.85 % w/v saline, 0.3 mL) four days before 
sacrifice. 
Blood samples from control mice and the immunized mice (on day 14 
after 3'^  booster) were collected. Three immunized mice were chosen randomly 
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and were anaesthetized by ether. Blood (0.4 mL) was obtained by heart 
puncture with a 1 ml syringe (25 gauge size needle) and allowed to clot 
overnight at room temperature. Sera was obtained by centrifugation (3,000 
r.p.m., 10 minutes). The samples were stored below -20。C for further analysis. 
The mice were allowed to recover for further studies. 
3.2.3 Hybridoma preparation 
I 
Methods described under this section, unless otherwise specified, were 
carried out in an aseptic atmosphere created by a laminar flow cabinet 
(SteriGARD Hood, Baker Company, Sanford, Ml, USA). All the reagents (tissue 
culture media, fetal bovine serum) and apparatus (tissue culture wares, 
dissecting instruments, medium bottles, pipettes) were sterilized before use, 
either by the manufacturers or by autoclaving (121 °C, 20 minutes). The tissue 
culture reagents were warmed to 37 °C before use. Cell densities ofvarious cell 
suspensions were measured by Coulter Counter (Model ZM with sampling 
stand, Coulter Electronics, U.K.). Centrifugation of the cell suspensions was . 
normally performed at 1,000 r.p.m. for 5 minutes. Cell cultures were incubated 
in a humidified automatic carbon dioxide (CO2) incubator (Forma Scientific, 
USA) at 37 °C under an atmosphere of 5.0% CO2. 
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3.2.3.1. Preparation of tissue culture working solutions 
Fetal bovine serum (FBS), purchased commercially in sterilized form, 
was heat inactivated at 56°C for 30 minutes before use, in order to inactivate 
serum reactive proteins (e.g. complements) which could damage the cells in 
culture, FBS was dispensed as 100 mL aliquots and stored at -20 °C prior to 
use. 
Dulbecco's modified Eagle's medium (DME) (4.5 mg/mL glucose) was 
j 
used as the basic culture medium,. Both DME and Dulbecco's phosphate | 
buffered saline (D-PBS) (0.01 M, pH7.2) were obtained commercially in powder 
form. One litre of DME or D-PBS was prepared by dissolving a package of 
DME or D-PBS powder (1 L) in double-distilled water (DD water) (700 mL). 
Sodium hydrogen bicarbonate (NaHCO3) (3.7 g, tissue culture grade) was 
added to the solution (no NaHCO3 was added in case of D-PBS) until fully 
dissolved. The pH ofthe solution was adjusted to 7.1-7.2 by either hydrochloric 
acid (1 M) or sodium hydroxide solution (1 M). DD water was then added to 
bring the volume to one litre. The solution was then sterilized by negative 
pressure filtration through a 0.22 j^m pore size filter membrane. The sterilized 
solution was dispensed into 500 mL air-tight bottles and stored at 4 °C prior to 
use. 
Culture medium which contains serum, antibiotics and other essential 
components is referred as complete medium. It has a short shelf-life after 
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mixing. Unless otherwise specified, all cells were cultured in complete DME (C-
DME) medium. C-DME was prepared with heat inactivated FBS (10 %, v/v), 
antibiotics (50 units/mL penicillin, 50 pg/mL streptomycin and 2.5 pg/mL 
fungizone) and L-glutamine (300 Mg/mL) in DME. For example, to prepare a 
100 mL solution of C-DME, 10 mL heat inactivated FBS, 1 mL penicillin-
streptomycin solution (stock = 100:1)，1 mL Fungizone solution (stock = 100:1) 
and 1 mL L-glutamine solution (stock = 100:1) were mixed with 87 mL DME. C-
DME was stored at 4 °C and discarded after two weeks storage. 
4 
Hybridoma selective medium (HAT medium) was prepared from C-DME, 
supplemented with sodium hypoxanthine (0.1 mM), aminopterin (0.4 pM) and 
thymidine (1.6 pM). This medium selectively allows the growth of successful 
fused hybrids. Hybridoma proliferation medium (HT medium), on the other 
hand, was prepared from, C-DME supplemented with sodium hypoxanthine 
(0.1 mM) and thymidine (1.6 pM). HT medium supports the continuous growth 
of selected hybridoma after the withdrawal of aminopterin. The theory of the 
use of these two media is described in the Section 3.1.3.4. in this chapter 」 
(Littlefield, 1964). The HAT or HT medium was prepared by dissolving 2 mL of 
the HAT or HT components solution (stock = 50:1) in 98 mL C-DME. Both 
media were stored at 4 °C prior to use and discarded after two weeks. 
A freezing medium is used in cryopreservation of cell lines. It is made up 
in DME supplemented with heat inactivated FBS (20 %, v/v) and dimethyl 
93 
sulfoxide (10 %, v/v). The freezing medium was prepared by adding 10 mL 
heat-inactivated FBS and 5 mL dimethyl sulfoxide to 35 mL DME. Freezing 
medium was stored at 4 °C and discarded after two weeks. 
3.2.4 Cells used in fusion experiments 
3.2.4.1 The myeloma cell line (NS-1) 
< 
The myeloma cell line used in the fusion experiments was known as 
P3/NS1/1-Ag4-1 (NS-1) (American Type Cell Culture Collection number TIB 
18). The cell line was kindly provided by the Department of Anatomy, the 
Chinese University of Hong Kong (CUHK). NS-1 cells are resistant to 10^ M 8-
azaguanine and do not grow in HAT medium. The cell line has been used 
extensively in cell fusion experiments. The cell synthesizes k chains but does 
not secrete free light chains. Intracellular k chains are only secreted in a hybrid 
cell when attached to heavy chains (Kohler and Milstein, 1976). NS-1 was 
normally cultured in 25 mL canted neck tissue culture flasks with C-DME (5 mL) 
and incubated in the automatic CO2 incubator. The cells were subcultured 
every three days when the cell monolayer had became 90 % confluent. The old 
medium was removed by aspiration and the cell monolayer was washed with 
D-PBS (5mL). The D-PBS was discarded and of trypsin-EDTA solution (0.05 
0/0 trypsin and 0.53 mM EDTA in D-PBS, 1 mL) (trypsinization) was added and 
incubated for 2 minutes at room temperature. Solution remaining in the flask 
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was removed by aspiration and the flask was further incubated at 37 °C for 10 
minutes in the automatic CO2 incubator. C-DME (2 mL) was then added to stop 
trypsin-EDTA action. The cell monolayer was dissociated from the flask by 
mechanical shaking. After all the cells were detached, the cell suspension was 
transferred for further experiment or maintained at a cell density of 2-3 x 10® 
cells/mL forfurther propagation. Due to mutation, HAT sensitive myeloma may 
sometimes revert to cell that grow in HAT medium. The reverted cells would 
decrease the chance of growth for the successfully fused hybrid. In order to 
ensure the HAT sensitivity of NS-1 and as a precaution, the cells were cultured 
in the presence of 8-azaguanine (20 pg/mL) two weeks before fusion. The 
culture medium used was prepared by mixing 1 mL 8-azaguanine solution 
(stock = 10:1) with 9 mL C-DME. 
Two 25 mL flasks of NS-1 (for one fusion experiment) were subcultured 
on the day before fusion and maintained at the density of 2-3 x 10® cells/mL. 
On the day offusion, an amount of 10? cells was obtained by trypsinization and 
resuspended in C-DME (5 mL). The cell viability of this cell suspension was 
determined by the trypan blue exclusion test (Section 3.2.4.3) and was greater 
than 90%. 
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3.2.4.2 Preparation of spleen cells from immunized mice and feeder cells 
Mice immunized with each immunogens tested to be anti-6-S-OHC-lgG 
positive were used as spleen cells donors. The mice were given final booster 
doses of immunogen (200 pg in 0.85% w/v saline, 0.3 mL) for four days just 
before fusion (Shibier et al., 1988). Each mouse was sacrificed by cervical 
dislocation and the whole body was washed with commercially available 
bleaching solution. The peritoneum was exposed by removing the covering 
skin. Ethanol (75%，v/v) was then sprayed on the peritoneum. After the ethanol 
was evaporated, the spleen was dissected out aseptically into a 144 x 21 mm 
tissue culture petri dish containing C-DME (15 mL). Spleen cells were released 
by injecting C-DME (10 mL) into the spleen with a 25 gauge size needle 
connected syringe. This caused the spleen to swell and release the cells (Zola, 
1987). Using sterile forceps and a syringe needle, spleen tissue was teased 丨 
quickly, but gently, until there was no further release of cells upon teasing 
apart. The suspension was transferred to a 15 mL centrifuge tube allowing 
large clumps to settle for 5 minutes. The cell suspension was then transferred 丨 
to another 15 mL centrifuge tube for centrifugation (1,000 r.p.m., 5 minutes). 
The supernatant was discarded and the cell pellet was loosed. Red blood cell 
lysing buffer (1 mL) was added to remove all red cells. After incubation for 2 
minutes at room temperature, D-PBS (10 mL) was added to stop the action of 
red blood cells lysing buffer and the cell suspension was then centrifuged 
(1,000 r.p.m., 5 minutes). A red blood cells free cell suspension was obtained 
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by resuspending the cells with C-DME (5mL). Normally, 5-7 x 10^ cells (1-2 
x1C)7 cells/mL) could be obtained by this method. 
Feeder cell suspension was prepared similarly from the spleen of an 
unimmunized mouse. However, the feeder cells were finally resuspended in 
HAT medium at a density of 2 x 10® cells/mL. The viabilities of these two cell 
suspensions were greater than 90 % by the trypan blue exclusion test. 
3.5.4.c Trypan blue exclusion test 
The cell suspension (100 pL) was mixed with trypan blue solution (0.4 
% ， 1 0 0 pL) in an eppendorff tube. After 3-5 minutes, the mixture was 
transferred to a haematocytometer and viewed under a light microscope 
(magnification = 200 x). About a hundred cells were counted and the number 




Cell viability X 100% (X = no. of blue stained cells) 
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3.2.5 Somatic cell fusion mediated by polyethylene glycol (PEG) 
The fusion procedure was modified from Zola's (1987) method. The 
spleen cell suspension from the immunized mouse was mixed with the NS-1 
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cell suspension in the ratio of 10:1. Spleen cell suspension of a total 7 x 10^ 
cells was mixed with 7 x 10® NS-1 cells and incubated at 37。C for 30 minutes. 
The cell mixture was then centrifuged (1,000 r.p.m., 5 minutes) to give a pellet. 
The pellet was resuspended in a prewarmed solution of DME (1 mL, pH 8.0) 
containing PEG (50 % w/v) and incubated at 37。C for exactly 45 seconds, with 
gentle mixing (Lane, 1985). DME (10 mL) was immediately added dropwise, 
with mixing, over 5 minutes to quench the action of PEG. A further 5mL of DME 
was added in the next 5 minutes. This was followed by incubation at 37。C for 
10 minutes and centrifugation (1,000 r.p.m., 5 minutes). Depending on the 
original amount of NS-1 cells mixed, the resulting hybrids were adjusted to the 
cell density o f4x 10' cells/mL in HAT medium, (e.g. i f7x 10®NS-1 were used, 
17.5mL HAT medium was added). An equal volume of feeder cell suspension 
previously prepared, was mixed with the hybrid suspension. The cell mixture 
was then plated at a volume of 1 ml per well in 24-well tissue culture plates and 
incubated at 37。C in a humidified CO2 incubator. 
I 
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3.2.6 Plate maintenance 
After 7 days of incubation, the HAT medium was replaced with fresh HT 
medium (1 mL/well). Growth of hybrid colonies was visible microscopically after 
another 7 days of incubation (day 14 after fusion). The growth of hybrids will 
turn the colour of the medium to yellow due to the excretion of acidic 
metabolites. The medium was collected and replaced by fresh HT medium (1 
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mL7well). When a positive anti-6-B-OHC antibody producerwas identified，the 
cells were isolated and subjected to the cloning step. 
3.2.7 Screening of hybridoma supernatant for anti-6-ft-OHC lgG activity 
Specific anti-6-R-OHC antibodies produced by the hybrids were detected 
by an ELISA as described below (Section 3.2.11). Supernatant from wells with 
hybrid colonial growth were collected and tested by ELISA. Positive wells were 
defined as those giving an absorbance approaching or greater than 0.5 in the 
i 




3.2.8 Cloning of the positive hybrids 
Positive antibodies producing hybrids must be cloned in order to ensure 
the monoclonality of the antibody produced and the homogenous growth of the 
I 
hybridoma. The method of limiting dilution (Lefkovits and Waldemann, 1979) 
was employed. Hybrid cells from positive wells were released from the bottom 
of the wells by pipetting the contents of the wells up and down for a dozen 
times. Hybrid cell suspension in HT medium of cell densities 100, 30 and 10 
cells/mL were prepared for cells from each positive well. e.g. positive hybrid 
suspension with a density 5 x 10® cells/mL was first diluted to 5000 cells/mL 
by adding 100 pL hybrid cell suspension to 10 mL HT medium. Then 200 pL 
ofthis suspension was diluted again in 10 mL HT medium, giving a 100 cell/mL 
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suspension. Finally, 3.3 mL and 1 mL of 100 cells/mL suspension were mixed 
with 6.7 mL and 9 mL HT medium to give the other two cell densities, 30 
cells/mL and 10 cells/mL, respectively. All dilutions were made in 15 mL 
centrifuge tubes. A feeder cells suspension (Section 3.2.4.2) of cell density 2 
X 1Q5 cells/mL was also prepared in HT medium. A 96-well culture plate was 
divided into 4 columns for each of the cell densities, with 100 pL of cell 
suspension from each cell density being added to each well of the 
corresponding columns. An equal volume (100 pL) of feeder cell suspension 
(2 X 1C)5 cells/mL) was also added to each well. The plate was then incubated 
for 14 days. Microscope observation was made on each well. Wells with more 
than one colony, asymmetrical colonies and those without hybrid growth were 
discarded. The supernatant ofthe remainder were screened again for specific 
anti-6-B-OHC antibodies by ELISA. 
3.2.9 Proliferation of established hybridoma 
Positive hybrids were allowed to increase cell mass and antibody 
production for further study. All the contents from a positive cloned well were 
transferred to a larger well in a 24-well plate with C-DME (1 mL/well) and 
I： 
incubated for a week. After cell growth showing 80 % confluency, the contents 
were transferred to a 25 mL tissue culture flask in C-DME (5 mL). Subculturing 
of the cell was done every five days as previously described for NS-1 cells 
(section 3.2.4.1) without trypsinization. The old medium was collected for 
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further investigation. 
3.2.10 Cryopreservation of myeloma and established hybridoma cell 
lines 
3.2.10.1 Freezing cells 
Cryopreservation is necessary to preserve cell lines indefinitely. A 25 mL 
I 
flask of NS-1 cells was prepared. An amount of 10? was obtained by 
subculturing step and the cell suspension was transferred to a 15 mL centrifuge 
tube. After centrifugation (1,000 r.p.m., 5 minutes), the cell density was 
adjusted to 5 x 10® cells/mL by freezing medium at 4。C’ (e.g. 2 mL of freezing 
medium was added to 10? cells to obtain a cell density of 5 x 10® cells/mL). The 
resulting cell suspension was dispensed into 1.8 mL freezing vials (1 mL/vial). 
The vials was then stored in a polystyrene foam box (1cm thick) at -70 °C 
overnight and the vials were transferred for storage in liquid nitrogen on the 
next day. The established hybridoma cell lines were also cryopreserved by the 
similar procedures. 
3.2.10.2 Thawing of cells 
1 vial (1 mL) offrozen NS-1 cells or established hybridomas (cell density 
=5 X 10® cells/mL) was withdrawn from the liquid nitrogen and put immediately 
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into a 37 °C water bath. After complete thawing, the contents were transferred 
to a 15 mL centrifuge tube containing C-DME (10 mL). After centrifugation 
(1,000 r.p.m., 5 minutes), the pellet was resuspended with C-DME (5 mL) and 
transferred to a 25 mL tissue culture flask for incubation. Growth of cell 
colonies became visible after a week. 
3.2.11 Enzyme-linked immunosorbent assay (ELISA) 
I ( 
Mouse antisera and all hybridoma supernatants were tested for specific 
anti-6-R-OHC lgG activity by ELISA as described previously in Chapter 2’ with 
some modifications. As shown in Fig. 3.2, microtitre plate (Falcon Microtest III) 
were coated with 6-R-OHC-BSA/OVA or OVA alone (0.1 mg/mL, 125 ML/well) 
• 
in coating buffer (0.05 M phosphate buffer, pH 7.2, contains 0.9 % w/v sodium 
chloride and 0.05 % v/v Tween 20’ freshly prepared) and shaken dry. All 
subsequent washes and all dilutions of sera and antisera were done with PBS-
Tween. The plate was then incubated at room temperature in a humidified 
chamber for one hour with each of the following reagents, with washing 
i 
between each incubation: hybridoma supernatant or test serum (100 ML/well) : 
at the initial dilution of 1:100 (5-fold) diluted down columns, goat anti-mouse 
！ 
lgG labelled with peroxidase (100 ML/well, 1:1000 dilution) and substrate 
solution (100 pL7well, containing 0.1 % v/v hydrogen peroxide and 400 ^lg/mL 
OPD in 0.15 M citrate-phosphate buffer, pH 5.0). The colour reaction was 
stopped after 20 minutes by the addition of H2SO4 (25 % v/v, 50 ML/well) and 
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Coat plates with 0.01 mg/ml 6-B-OHC-OVA/OVA 
in coating buffer: 125 ^iL/well 
• 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with test samples for 1 hour at room temperture 
• 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with peroxidaes-labelled goat anti-mouse lgG 
(1.1000)，100 pL/well for 1 hour at room temperture 
• 
Wash 3 times with PBS-Tween and shake dry 
• 
Incubate with OPD substrate solution: 100 pL/well for 
20 mins. at room temperture 
• 
Stop reaction by adding 25 % H2SO4: 50 pL/well 
• 
Read absorbance at 490 nm 
Firure 3.2. Flow diagram of ELISA procedures for the 
detection of mouse anti-6-Ii-OHC lgG activity 
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the absorbance at 490 nm was measured by a dual wavelengths automatic 
microplate reader (Dyntech Laboratory model MR 710, USA) with the reference 
wavelength set at 630 nm. 
Anti-6-B-OHC activity was defined as the antibody titre following coating 
with 6-ll-OHC-OVA where no activity was detected with unconjugated OVA. 
Antibody titres were calculated as the dilution of anti-serum giving an 
absorbance of 0.5. 
To determine the intra-assay coefficient, the supernatant collected from 
hybridoma clone 19F (100 MU 1:3,000 dilution) was added to each well of a 6-
B-OHC-BSA coated plate. The plate was then subjected to the ELISA 
procedures as described previously. Intra-assay coefficient was calculated as 
the coefficient of variation (standard derivation/mean x 100 %) between 96 
If 
wells on the plate. Four 96-well plates were set up with the same treatment and 
the interassay coefficient was calculated as the mean coefficient of variation 
between these plates. The two coefficients of 5C1 hybridoma supernatant (1:30 
dilution) were also determined by a similar method. 
3.2.12 Inhibition ELISA analysis 
To confirm the specificity of the monoclonal antibodies developed 
against 6-R-OHC, hapten inhibition studies similar to that described previously 
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in Chapter 2 were set up to detect any cross reactivity of the antibodies. Serial 
dilutions ofvarious inhibitorswere prepared. Aliquots (150 pL) of each inhibitor 
were mixed with diluted hybridoma supernatant (150 [^ L, 1:3,000 for 
monoclonal antibody 19F and 1:30 for 5C1) in a glass test tube. The mixture 
was incubated overnight at 4 °C. The supernatant (100 [jL) was assayed 
directly by ELISA. The inhibitors used include the 6-R-OHC conjugated carrier 
proteins (6-I^OHC-BSA，6-R-OHC-OVA and 6-li-OHC-HSA), the unconjugated 
carrier protein (BSA, OVA and HSA), and other steroids listed in Table 2.1 
(Chapter 2). A methanol control was used in the hapten inhibition studies, since 
all the steroids were initially dissolved in methanol. 
3.2.13 Calculation of cross reactivity 
Calculation of the cross reactivities of the monoclonal antibody, 
expressed as cross reactive percentage, CR%, was similar to that described 
in Chapter 2 (Section 2.2.6). Briefly, the respective 50% inhibition concentration 
I 
I 
(IC50) of each steroid was determined by extrapolation of the inhibition curve. 
The CRo/o of each steroid is calculated as: 
IC50 of 6-R-OHC 
CR% = X 100% 
IC50 of the steroid 
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3.2.14 Applications of mouse anti-6-B-OHC monoclonal antibody (19F) 
on ELISA method for determination of urinary 6-li-OHC in human 
and animal model. 
3.2.14.1 Quantification of 6-R-OHC in human urine samples by monoclonal 
antibody-based ELISA 
The human urine sample collected in the experiment described in 
Chapter 2 was used in this study. The urine samples (15 pl), both before (day 
1 control sample) and after drug treatment (day 5 sample) were transferred to 
a glass test tube and mixed with 135 pl PBS-Tween buffer; monoclonal 
antibody 19F (150 pl, 1:3,000 dilution) was added to each tube, which were 
then sealed and incubated at4°C overnight. On the next day, aliquots (100 pl) 
ofthe supernatant were assayed by inhibition ELISA as described previously 
(Section 3.2.12). The level of 6-R-OHC in each urine sample was determined 
by matching the absorbance to the corresponding concentration on the 
1 
inhibition standard curve of 6-B-OHC, obtained as described in inhibition ELISA 
studies (Section 3.2.12). 
3.2.14.2 Quantification of 6-R-OHC in rat urine samples by ELISA 
As for the human urine studies, the rat urine sample described in the 
chapter 2 was used in this study. The urinary 6-R-OHC level in rat urine 
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samples were determined by the monoclonal antibody (19F) based inhibition 
ELISA as described in human urine study (Section 3.2.14.1). 
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3.3. Results 
3.3.1. Anti-6-li-OHC lgG activity in immunized mice sera 
Two mice were chosen randomly from the immunized group. The sera 
from these two mice showed strong anti-6-B-OHC lgG activity with the antibody 
titre about 1 in 5 x 10^ and 1 in 5 x 10® respectively (Fig. 3.3a). The sera taken 
from mouse 1 and 2 were inhibited after pre-incubated with 6-B-OHC 
conjugated proteins (6-R-OHC-BSA，6-R-OHC-OVA and 6-B-OHC-HSA) 
however, no significant anti-protein carriers (BSA, OVA and HSA) activity was 
observed (Fig. 3.3b and Fig. 3.3c). These mice were used in the fusion 
experiments. 
3.3.2. Hybrid growth and screening of anti-6-R-OHC antibodies 
Two weeks after fusion experiments, a total of 72 wells were plated and 
80% of those wells showed hybrid growth. All these wells were screened twice 
by ELISA for any anti-6-S-OHC antibody activity and only the supernatant from 
two wells showed positive for anti-6-R-OHC activity. These wells were then 
isolated and subjected to cloning. 
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Figure 3.3a Anti-6-S-hydroxycortisol lgG activity in the serum taken 
on day 14th after the 3rd booster of 6-B-OHC-OVA injection in 2 mice. 
Anti-6-R-OHC lgG activity was measured by ELISA (n=6) 
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Figure 3.3b Inhibition ELISA test of anti-6-B-hydroxycortisol lgG activity 
after preincubation of antiserum taken from mouse 1 (1: 5 xlO^ dilution) 
with various protein conjugates (6-B-OHC-BSA, 6-R-OHC-HSA and 6-
S-OHC-OVA) and carrier protein (BSA). (n=6) 
Note:Other two carrier proteins (OVA & HSA) showed inhibition curves 
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Figure 3.3b Inhibition ELISA test of anti-6-R-hydroxycortlsol lgG 
activity after preincubation of antiserum taken from mouse 2 (1: 5 x10^ 
dilution) with various protein conjugates (6-R-OHC-BSA. 6-R-OHC-HSA 
and 6-S-OHC-OVA) and carrier protein (BSA). (n=6) 
Note:Other two carrier proteins (OVA & HSA) showed inhibition curves 
similar to that of BSA they were omitted in this figure. 
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3.3.3. Screening of hybridoma clones 
Two weeks after all the hybrids were cloned by the method of limiting 
dilution. Two clones namely 5C1 and 19F, which secrete specific monoclonal 
anti-6-li-OHC lgG, were successfully developed. The anti-6-R-OHC lgG 
activities of hybridoma clones 5C1 and 19F are shown in Fig. 3.4 and Fig. 3.5 
respectively. Similarly, no significant anti-protein carriers (BSA, OVA and HSA) 
activity was detected. The antibody titres of 5C1 and 19F were 1 in 100 and 1 
in 5x1Q4 dilution respectively. 
：存！ 
3.3.4. Characterization of monoclonal antibody (5C1) 
As shown in Fig. 3.6，the ELISA reaction of 5C1 were inhibited after 
preincubated with 6-(i-OHC conjugated proteins (6-B-OHC-BSA, 6-S-OHC-OVA 
and 6-R-OHC-HSA), however, but not inhibited by those protein carries (BSA, 
OVA and HSA). The antibody also cross reacted with three structurally similar 
steroids, they are in the order ofgreatest response, 6-B-OHC-21-Ac, 6-S-OHC-
Ac-CMO, 6-a-OHC and 6-B-OHC, as showed in Fig. 3.7 and Table 3.2. The 
antibody exhibited a dose-response range for 6-B-OHC within 10 ng -10 pg/ml. 
Stereo-specific discrimination between 6-a-OHC and 6-B-OHC stereoisomer 
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Figure 3.4 Anti-6-l^hydroxycortisol lgG activity in the supernatant 
of hybridoma clone 5c1 as compared to the supernatant of myeloma 
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Fiigure 3.5 Anti-6-R-hydroxycortisol lgG activity in the supernatants 
of hybridoma clone 19F as compared to the supernatant of myeloma 
cell (NS-1). Anti-6-R-OHC lgG activity was measured by ELISA. (n=6) 
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Figure 3.6 Inhibition ELISA test of anti-6-B-hydroxycortisol lgG activity 
after preincubation of hybridoma supernatant (5C1, 1:30 dilution) with 
various protein conjugates (6-R-OHC-BSA, 6-IVOHC-HSA and 6各 
OHC-OVA) and carrier protein (BSA). (n=6) 
Note:Othertwo carrier proteins (OVA & HSA) showed inhibition curves 
similar to that of BSA they were omitted in this figure. 
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Figure 3.7 Inhibition ELISA test of anti-6-R-hydroxycortisol lgG activity 
after preincubation of hybridoma supernatant (5C1 ’ 1:30 dilution) with 
various 6-R-hydroxycortisol steroids, (n=6) 
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Table 3.2. Cross reactivities of anti-6-R-hydroxycortisol monoclonal 
antibodies 5C1 with various steroids 
Cross reacting species IC50 CR% 
6-R-OHC 0.5 Mg/ml 100 
6-R-OHC protein conjugates: 
6-H-OHC-BSA 0.1 Mg/ml >100 
6-(i-OHC-HSA 0.1 Mg/ml >100 
6-(i-OHC-OVA 0.3 Mg/ml >100 
6-R-OHC steroids: 
6-R-OHC-21-Acetate 0.08 pg/ml >100 
6-(i-0HC-Ac-CM0 0.05 pg/ml >100 
6-a-OHC 0.3 Mg/ml >100 
Other cross reacting steroids: 
Cortisone 80 pg/ml <1 
Corticosterone 10pg/ml 5 
Hydrocortisone 0.5 Mg/ml 100 
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corticosterone and hydrocortisone (Fig. 3.8). As listed in Table 3.2, 
hydrocortisone exhibited an unexpectedly high degree of cross reactivity with 
the antibody (CR%=100%), whereas only 5 % and less than 1 % of cross 
reactivities were observed for corticosterone and cortisone. All other tested 
steroids, their IC50 were well outside the investigation concentration and their 
CRo/o were smaller than 1 % and are not listed in Table 3.2. 
3.3.5. Characterization of monoclonal antibody (19F) 
As shown in Fig. 3.9, hapten inhibition ELISA showed inhibition with 6各 
OHC conjugated proteins (6-R-OHC-BSA, 6-S-OHC-OVA and 6-S-OHC-HSA) 
when these were preincubated with the hybridoma clone (19F) supernatant. 
However, no inhibition was shown with the carrier proteins (BSA, OVA and 
HSA). The results confirmed that the antibody secreted from hybridoma (19F) 
clone can recognize 6-R-OHC residues on the conjugated proteins. 
The antibody activity was inhibited by in 6-R-OHC-Ac-CMO, 6-R-OHC-
21-Ac and 6-a-OHC. Their inhibition curves are showed in Fig. 3.10 and their 
cross reactivities and IC50Values are listed in Table 3.3. The antibody (19F) has 
higher affinities for 6-S-OHC-Ac-CMO and 6-B-OHC-Ac than 6-S-OHC. 
Moreover, the antibody showed a dose-response relationship to 6-li-OHC 
within the concentration range 0.2 - 20 pg/ml. Three steroids which show cross 
reactivities of greater than 1 % (Table 3.3) are cortisone, hydrocortisone and 
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Figure 3.8 Inhibition ELISA test of anti-6-R-hydroxycortsiol lgG 
activty after preincubation of hybridoma supernatant ( 5C1，1:30 
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Figure 3.9 Inhibition ELISA test of anti-6-R-hydroxycortisol lgG 
activity after preincubation of hybridoma supernatant (19F, 1:3,000 
dilution) with various conjugated proteins (6-R-OHC-BSA, 6-S-OHC-
HSA & 6-B-OHC-OVA) and carrier protein BSA. (n=6) 
Note: Other two carrier proteins (OVA & HSA) showed inhibition 
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Figure 3.10 Inhibition ELISA test of anti-6-B-hydroxycortisol lgG 
activity after preincubation of hybridoma supernatant (19F, 1:3,000 
dilution) with various 6-R-hydroxycortisol steroids, (n=6) 
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Table 3.3. Cross reactivities of anti-6-6-hydroxycortisol monoclonal 
antibodies 19F with various steroids 
Cross reacting species IC50 CR% 
6-R-OHC 0 .8^ /m l 100 
6-R-OHC protein conjugates: 
6-R-OHC-BSA 0.5pg/ml >100 
6-R-OHC-HSA 0.6 Mg/ml >100 
6-B-OHC-OVA 0.8 Mg/ml 100 
6-R-QHC steroids: 
6-R-OHC-21-Acetate 1 pg/ml 80 
6-R-OHC-Ac-CMO 0.3 pg/ml >100 
6-a-OHC 4 Mg/ml 50 
Other cross reacting steroids: 
Cortisone 7pg/ml 10 
Hydrocortisone 20 Mg/ml 4 
6-R-Hydroxycortisone 8 Mg/ml 10 
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respectively, and their cross-reactivities were between 1 to 10 %. In addition, 
Fig. 3.11 shows the inhibition curves of these three steroids as compared with 
6-B-OHC. All other tested steroids, their IC50 were well outside the investigated 
concentration range and their CR% were smaller than 1 %, they were not 
considered as cross reacting species and were not listed on Table 3.3. 
By comparing of the two monoclonal antibodies in terms of their 
specificity and sensitivity, 19F appears to be better than that of 5C1 in relation 
to the aim of this study, also the subsequent studies were focused only on the 
19F monoclonal antibody. 
3 . 3 . 6 . Quantification of 6-B-OHC concentration in urine samples by 
ELISA using monoclonal antibody (19F) 
3.3.6.1. Determination of 6-R-OHC level in human urine samples 
The total 24 hours 6-B-OHC concentration in human urine detected by 
hapten inhibition ELISA using monoclonal antibody (19F) is shown in Fig. 3.12. 
The urinary 6-R-OHC concentration collected in 24 hours was significantly 
elevated from 485 土 100 pg/24hrs on day 1 control sample to 1478 土 281 
Mg/24hrs on day 5 sample, (after rifampicin treatment) (p^0.001). Furthermore, 
as compared to the previous study on human urinary 6-B-OHC using polyclonal 
antibody R1-2B, Fig. 3.13 showed that there was no significant difference 
between using monoclonal antibody 19F and polyclonal antibody R1-2B in 
ELISA tests for the detection of 6-R-OHC concentration in human urine 
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Figure 3.11 Inhibition ELISA test of anti-6-(i-hydroxycortisol lgG 
activity after preincubation of hybridoma supernatant (19F, 1:3,000 
dilution) with various steroids, (n=6) 
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Figure 3.12 The total amount of 6-R-hydroxycortisol (24 hours) in 
human urine before and after rifampicin administration (600 mg/day 
for 4 days). The 6-(l-hydroxycortisol was determined by monclonal 
antibody 19F based hapten inhibition studies with ELISA. Results 
are presented as the mean (SD). ( **P<0.001 by Student's paired t-
test, n=6) 
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Figure 3.13 Comparison between using monoclonal and polyclonal 
antibody based ELISA to detect the total amount of urinary 6-Q>-
hydroxycortisol (24 hours) in human before and after rifampicin 
administration ( 600mg/day for 4 days). Results are presented as 
the mean (SD). ( **P<0.001 by Student's paired t-test, n=6 ) 
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samples. 
3.3.6.2. Determination of 6-B-OHC level in rat urine samples 
The total 24 hours urinary 6-R-OH concentrations in the rats after 
various drug administration were measured by hapten inhibition ELISA using 
monoclonal antibody 19F. As shown in Fig. 3.14, there was a large and 
significant increase in 24 hours urinary 6-B-OHC concentration after rifampicin 
administration (increased from 30 ± 15 fjg/24hrs on day 1 sample to 5230 士 
549 pg/24hrs on day 5 samples) _ . 0 0 1 ) . As shown in Fig. 3.15，a significant 
reduction in total 24 hours urinary 6-R-OHC concentration were observed after 
the administration of ketoconazole (25 士 15 pg/24hrs on day 1 control sample 
decreased to 0.07 士 0.03 ng/24hrs on day 5 sample) (p<0.001). In addition, 
cimetidine (Fig. 3.16) and nifedipine (Fig. 3.17) also inhibited rat 24 hours 
urinary 6-B-OHC production. 
The total 24 hours urinary 6-S-OHC concentrations in human and rats 
under the influence of various enzyme inducers and inhibitors are summarized 
in the Table 3.4., which also includes a comparison of the polyclonal antibody 
R1-2B and monoclonal antibody 19F for detection of rat 24 hours urinary 6-Q>-
OHC level. Both polyclonal antibody R1-2B and monoclonal antibody 19F have 
shown similar quality in detection of 6-R-OHC in rat urine (Table 3.4). 
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Figure 3.14 The total amount of urinary 6-R-hydroxycortisol (24 
hours) in rats before and after rifampicin administration 
(80mg/kg/day for 4 days). The 6-R-hydroxycortisol was determined 
by monoclonal antibody 19F based hapten inhibition ELISA. 
Results are presented as the mean (SD). ( **P<0.001 by Student's 
paired t-test, n=6) 
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Figure 3.15 The total amount of urinary 6-R-hydroxycortisol (24 
hours) in rats before and after ketoconazole administration 
(30mg/kg/day for 4 days). The 6-B-hydroxycortisol was determined 
by monoclonal antibody (19F) based hapten inhibition ELISA. 
Results are presented as the mean (SD). ( **P<0.001 by Student's 
paired t-test, n=6) 
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Figure 3.16 The total amount of urinary 6-R-hydroxycortisol (24 
hours) in rats before and after cimetidine administration (80mg/kg/day 
for 4 days). The 6-B-hydroxycortisol was determined by monoclonal 
antibody (19F) based hapten inhibition ELISA. Results are presented 
as the mean (SD) ( **P<0.001 by Student's paired t-test, n=6 ) 
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Figure 3.17 The total amount of urinary 6-B-hydroxycortisol (24 
hours) in rats before and after nifedipine administration (50mg/kg/day 
for 4 days). The 6-R-hydroxycortisol was determined by monoclonal 
antibody (19F) based hapten inhibition ELISA. Results are presented 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.7. Intra- and inter-assay coefficients 
The intra-assay coefficients of variation between 96-wells on the same 
plate for anti-6-(i-OHC lgG activity of monoclonal antibodies 5C1 (1:30 dilution) 
and 19F (1:3,000 dilution) were 5.2 % and 6.4 %, respectively. The inter-assay 
coefficient variation between duplicate treatment on each of six separate 




In this study, two monoclonal antibodies, 5C1 and 19F, directed against 
6-B-OHC were developed. As in the previous studies with rabbits antisera, 
(Chapter 2) three criteria were set out as the prerequisites for the specific 
identification of anti-6-R-OHC antibody. Both monoclonal antibodies did not 
cross react with the carrier proteins, but were inhibited by 6-R-OHC conjugated 
proteins and 6-S-OHC itself. However, the two monoclonal antibodies were 
different in terms of their cross reactivities and sensitivities to 6-R-OHC and 
related steroids. 
Monoclonal antibody 19F exhibited a stronger interaction with 6-B-OHC-
Ac than 6-(i-OHC, but was unable to differentiate between its stereoisomer 6-a-
OHC. This finding was rather expected, because it has been suggested that 
prime recognition sites on the immunogen should be distal to the site of 
conjugation at the C3 position (Niswender and Midgley, 1970; Spector and 
Parker, 1970; Bauminger etal., 1974). Therefore, the antibody produced by 
this immunogen appears to be insensitive to the isomeric change at the C6 
position. However, this finding is not in accord with previous studies on the 
development of monoclonal antibody against 5a-estrane-3S, 17a-diol (Chu, 
1992)，in which good differentiation between the 17a and MQ> isomers was 
obtained. The antibody also showed inhibition with other three steroids, 
cortisone, hydrocortisone and 6-R-hydroxycortisone, but their cross reactivities 
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were less than 10 %. The antibody recognizes 6-R-OHC as low as 0.2 pg/ml. 
The normal human urinary 6-(l-OHC level were within 400 - 600 \^ g (Ohnhaus 
et al； 1989 and Ged et al., 1989) which are well within the sensitivity range of 
the monoclonal antibody (19F). 
The cross reactivity of monoclonal antibody 5C1 is rather different from 
that of 19F. The former antibody exhibited an unexpectedly high degree of 
cross reaction with hydrocortisone (CR%=100%). The only possible 
explanation is the hybridoma secreting this antibody might be a descendant of 
an antibody producing cell which has a broad specificity to steroids related to 
the 6-R-OHC structure. It should be noted that the cross reactivity of this 
antibody has not been entirely clarified due to the poor aqueous solubility ofthe 
steroids. Other tested steroids not listed as cross reacting species (Table 3.5) 
had cross reactivities smaller than 2 %. Therefore, due to its unexpected high 
specificity to steroids related to 6-B-OHC, monoclonal antibody (5C1) was not 
used in subsequent studies. 
Table 3.6 summarized the cross reactivity and sensitivity of anti-6-(i-
OHC monoclonal antibodies (5C1 and 19F) and polyclonal antiserum R1-2B. 
The specificities and sensitivities of monoclonal anti-steroid antibodies were not 
significantly improved when compared with polyclonal antiserum produced by 
conventional methods (Fantl and Wang, 1983; Al-Dujaili et a/.，1984). More 
fusion experiments may be necessary to produce hybridomas which secrete 
desired monoclonal antibodies with better sensitivity and specificity 
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Table 3.5. Comparison on cross reactivitiy and sensitivity of two anti-6-(i-
hydroxycortisol monoclonal antibodies named 5C1 and 19F 
Monoclonalantibodies: 6C1 19F 
Cross reactivity in % 
6-R-QHC protein conjugates: 
6-B-OHC-BSA >100 >100 
6-B-OHC-HSA >100 >100 
6-B-OHC-OVA 100 100 
6-R-OHC steroids: 
6-(l-OHC-21-Acetate >100 80 
6-B-OHC-Ac-CMO >100 >100 
6-a-OHC >100 50 
6-R-OHC 100 100 
Other cross reacting steroids: 
Cortisone <1 10 
Corticosterone 5 <1 
Hydrocortisone 100 5 
6-R-Hydroxycortisone <1 10 
Sensitivity in inhibition ELISA: 0.1pg/ml 0.2^jg/ml 
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Table 3.6. Comparison on cross reactivity and sensitivity of two anti-6-R-
hydroxycortisol monoclonal antibodies (5C1 and 19F) with rabbit 
polyclonal antibody R1-2B 
Polyclonal Antibody Monoclonal Antibody 
R1-2B 6C1 19F 
Cross Reacting Species: Cross Reactivity (CR%) 
6-B-OHC 100 100 100 
6-ft-OHC protein conjugates: 
6-R-OHC-BSA >100 >100 >100 
6-B-OHC-HSA >100 >100 >100 
6-R-OHC-OVA 0.1 100 100 
6-&-OHC steroids: 
6-B-OHC-21-Acetate >100 >100 100 
6-R-OHC-Ac-CMO >100 >100 >100 
6-a-OHC >100 >100 50 
Other cross reacting steroids: 
Cortisone 1 <1 10 
Corticosterone <1 5 <1 
6-R-Hydroxycortisone 2.5 <1 10 
Hydrocortisone 1-6 100 5 
Sensitivity in 
inhibition ELISA: 1 ng/ml 0.1 pg/ml 0.2 pg/ml 
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characteristics (De Lauzon et al., 1990). The abilities of both monoclonal 
antibodies, 5C1, 19F and polyclonal antiserum R1-2B, to recognize 6-B-OHC 
was comparable to the level of urinary 6-R-OHC in human (baseline level 400 -
600 pg) in other studies (Ohnhaus et al” 1989 and Ged et al” 1989). However, 
the high level cross reaction of monoclonal antibody (5C1) with structurally 
similar steroids made it not suitable for quantifying 6-B-OHC in urine. The 
monoclonal antibody 19F and polyclonal antiserum R1-2B were equally good 
in terms of their specificity and sensitivity, making these two antibodies useful 
for detecting and quantifying urinary 6-li-OHC. 
In the studies on human urine sample, the total 24 hours urinary 6-R-
OHC values before and after rifampicin treatment were 485 士 100 pg/24hrs 
and 1478 士 281 pg/24hrs respectively, which was comparable to the results 
obtained from previous study by radioimmunoassay (Ohnhaus etal., 1989 and 
Bammel etal” 1992). 
In other studies on rat urine sample, the effect of one enzyme inducing 
agent and three enzyme inhibiting agents on 24 hours urinary 6-B-OHC output 
were investigated using monoclonal antibody 19F. Rifampicin exhibited a 
significant enzyme inductive effects on rat 24 hours urinary 6-R-OHC output 
(Fig. 3.14). On the other hand, enzyme inhibitory effects by ketoconazole (Fig. 
3.15)，cimetidine (Fig. 3.16) and nifedipine (Fig. 3.17) were observed. These 
effects were comparable to previous findings (Steven et al” 1994; Shinn et al., 
1992). As shown in Table 3.4，there was no significant difference between 
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using polyclonal antibody R1-2B and monoclonal antibody 19F on inhibition 
ELISA method for quantifying the changes of 24 hours 6-R-OHC concentration 
in urine. It is therefore that both methods were sufficiently sensitive and specific 
enough for the detection of the changes of 6-li-OHC concentration in human 
and rat urine. 
In summary, the hybridoma technique in this study produced two 
monoclonal antibodies against 6-R-OHC, 5C1 and 19F, which express different 
sensitivities to 6-R-OHC and cross reactivities to various steroids. Monoclonal 
antibody clone (19F) appears to be a better and more specific for 6-S-OHC 
recognization. There was no significant improvement in the sensitivity as well 
as specificity to 6-R-OHC when the monoclonal antibody 19F was compared 
to the polyclonal antibody R1-2B. Both antibodies were specific for 6-(i-OHC. 
When compared to other studies by radioimmunoassay, this monoclonal 
antibody clone (19F) based ELISA showed a similar sensitivity and accuracy. 
This monoclonal antibody clone (19F) based ELISA method should be useful 
as an alternative for the detection of urinary 6-(i-OHC, given that the quality of 




Measurement of changes in urinary 6-R-OHC output by RIA and HPLC 
has been used as one of the best endogenous indicators of human CYP IIIA 
enzyme activity (Frantz efa/.，1961; Dumont etal” 1984; Ohnhaus etal” 1989 
and lnoue et al., 1994). In this study, a monoclonal antibody based ELISA was 
developed for quantification of urinary 6-R-OHC concentration. 
A polyclonal antiserum (R1-2B) against 6-R-OHC was first developed in 
this study to provide a screening method for the detection of specific anti-6-R-
OHC monoclonal antibody. In this study, the 6-B-OHC was conjugated to a 
carrier protein [(BSA), bovine serum albumin] by substitution of a CMO group 
at the C3 position. The immunization of this 6-B-OHC conjugate gave rise to 
specific anti-6-B-OHC antibodies in rabbit. Based on the results obtained from 
the ELISA test using polyclonal antibody (R1-2B), the antibody titre of the 
assay was in 1:500,000 dilution, the assay had a sensitivity of 1 ng/ml (p<0.05), 
intra- and inter-assay coefficients were 3.1% and 5.2%, respectively. The 
specificity ofthe assay was determined by hapten inhibition studies according 
to the criteria previously described (Yeung et al., 1985), where the antibody 
recognized 6-li-OHC at a concentration as low as 1 ng/ml with a maximum 
concentration of 100 pg/ml. Cross reactivity with otherthree structurally related 
steroids (cortisone, hydrocortisone and 6-R-hydroxycortisone) did not exceed 
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5%. The accuracy of this assay against this 6-R-OHC was found to be 
comparable to other methods using RIA [0.025 ng/ml (Park 1978)]，ELISA 
[0.075 ng/ml (Shehnaz et a/” 1994)] and HPLC [0.68 ng/ml (Inoue et al” 
1994)]. Therefore, the ELISA method based on this antiserum was specific and 
sensitive enough as a screening test for the development of monoclonal 
antibody against 6-R-OHC. Since the sensitivity of the assay based on this 
antiserum was also found to be within the range for the detection of 6-B-OHC 
in normal human urinary output (100-400 pg) (Nakamura and Yakata, 1989; 
Chul, 1995), the polyclonal anti-6-S-OHC antibody-based ELISA was used to 
measure the changes of 6-B-OHC in human. The changes in 24 hours 
concentration of 6-R-OHC was investigated using rifampicin, a well known 
enzyme inducer, to volunteers. The total 24 hours urinary 6-li-OHC 
concentration was increased from 370 士 105 Mg/24hrs (control samples) to 
1350 士 201 pg/24hrs (samples after administration of rifampicin, 600 mg/day 
for 4 days). These values were consistent with results obtained from previous 
studies using RIA (Ohnhaus et al., 1989 and Bammel et al., 1992). In the 
animal studies, the enzyme inducer, rifampicin caused a significant enzyme 
induction as indicated by the increased in 24 hours urinary 6-R-OHC 
concentration in the rats. Enzyme inhibitors were also investigated in this 
studies, with ketocanzole being the most potent inhibitors followed by 
cimetidine and nifedipine. These results confirmed the results from previous 
studies that these drugs can affect the CYP IIIA4 enzyme activities, which also 
further confirmed the ELISA based on this antibody (R1-2B) was useful and 
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sensitivity enough to detect the changes of 6-S-OHC in rat and human urine. 
Monoclonal antibodies against 6-R-OHC were then developed for its 
detection in human and rat urine by ELISA. Two monoclonal antibodies have 
been raised according to the modified hybridoma technique (Zola, 1987). Two 
hybridoma clones, 5C1 and 19F which secrete anti-6-R-OHC monoclonal 
antibodies were developed following fusion of NS-1 myeloma cells and spleen 
cells from C57 mice immunized with 6-R-OHC-3-carboxymethyloxime-bovine 
serum albumin. Clone 19F, the antibody titre was as low as 1 in 5x10^ dilution, 
the assay had a sensitivity of 200 ng/ml (p<0.05), intra- and inter-assay 
coefficients were 6.4 % and 7.3 %, respectively. The specificity of the assay 
was also determined by hapten inhibition studies, where the antibody 
recognized 6-B-OHC at a concentration as low as 0.2 Mg/ml with a maximum 
concentration of20 pg/ml. Monoclonal antibody 19F exhibited stronger reaction 
with 6-R-OHC-Ac than 6-R-OHC, but is unable to differentiate from its 
stereoisomer 6-a-OHC. This finding was rather expected, because it has been 
suggested that the prime recognition site on the immunogen should be distal 
to the site of conjugation at C3 position (Niswender and Midgley, 1970; Spector 
and Parker, 1970; Bauminger et al., 1974)，therefore, the antibody produced 
by this immunogen appear to be insensitive to the isomeric changes in C6 
position. However, this finding is not in accord with the previous studies on the 
development of monoclonal antibody against 5a-estrane-3S-17a-diol (Chu, 
1992), in which good differentiation between the 17a and MQ> isomers was 
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obtained. The antibody also showed some inhibition with other three 
structurally related steroids, cortisone, hydrocortisone and 6-Q>-
hydroxycortisone, but their cross reactivities were less than 10 %. Clone 5C1, 
was less specific than the monoclonal antibody 19F to 6-(i-OHC, and exhibited 
an unexpected high degree of cross reaction with hydrocortisone (CR% = 
100%). Therefore, only the monoclonal antibody clone 19F was specific and 
sensitive enough for use in the detection of 6-fi-OHC concentration. Thus, the 
ELISA based on this antibody was then used to quantify the 24 hours 6-R-OHC 
concentration in human and rat urine. In human study, the total 24 hours 
urinary 6-R-OHC values before and after rifampicin treatment were 485 士 100 
pg/24hrs and 1478±281 Mg/24hrs respectively, which was comparable to the 
results obtained from previous study by radioimmunoassay (Ohnhaus et a/.， 
1989; Bammel et al., 1992). In other studies on rat urine sample, the effect of 
one enzyme inducing agent and three enzyme inhibiting agents on 24 hours 
urinary 6-R-OHC output were investigated. The well known enzyme inducer, 
rifampicin exhibited a significant enzyme inductive effects on rat 24 hours 
urinary 6-S-OHC output. On the other hand, enzyme inhibitory effect by 
ketocanazole, cimetidine and nifedipine were observed. These effects were 
comparable to previous findings (Steven et a/.，1994; Shinn et al., 1992). In 
addition, there was no significant difference between using polyclonal antibody 
R1-2B and monoclonal smtibody 19F for quantifying the changes in 24 hours 
6-B-OHC concentration in both human and rat urine. Therefore it is further 
confirmed that the monoclonal antibody clone 19F was sufficiently sensitive 
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and specific for the detection of the changes of 6-R-OHC concentration in 
human and rat urine. 
As outline in table 4.1, there was no significant improvement in terms of 
cross reactivity when monoclonal antibody was used as compared to R1-2B. 
There was also no improvement in sensitivity with the monoclonal antibody (1 
ng/ml in R1-2B to 200 ng/ml in 19F). The ELISAs in this study have comparable 
precision and reproducibility when their intra- and inter-assay coefficients are 
compared with other detection methods (Table 4.1). Although the sensitivity of 
ELISA methods in this study are comparatively lower than in the other studies 
(Table 4.1), both 19F and R1-2B in ELISA are still sensitive enough to be used 
to quantify the urinary 6-B-OHC concentration in human and animal urine 
samples. In addition, the specificity of ELISAs are also well within the 
acceptable level. Therefore, it can be concluded that the currently developed 
ELISA for 6-S-OHC, using either polyclonal antiserum R1-2B or monoclonal 
antibody 19F, is an accurate method for routine measurement of 6-(i-OHC in 
urine samples. 
In addition, results in this study suggested that the specificity and 
sensitivity may not be necessarily improved in monoclonal antibodies when 
compared with polyclonal antisera. The success of developing a suitable 
antibody very much depends on chance. More fusion experiments may 













































































































































































































































































































































specificity and sensitivity. In addition, although the monoclonal antibody 19F 
only exhibited a similar sensitivity and specificity as polyclonal antiserum, the 
antibody 19F had some real advantages over the antiserum R1-2B. These 
advantages included 1). the background interference absorbance (〜0.3) 
observed in the hapten inhibition ELISA method using this antiserum can be 
avoided in the monoclonal antibody based ELISA. This interference causes a 
decrease in the sensitivity of the ELISA as a result ofthe non-specific binding 
between the thiol or disulphide groups on the ovalbumin of the coated steroid-
protein conjugate with certain immunoglobulins in the antiserum (Mohammad 
et al” 1983) and 2). due to their potential unlimited supply and their activity 
remaining constant over a long period oftime, the standardization ofthe ELISA 
would be better for monoclonal antibody clone (19F) rather than polyclonal 
antiserum R1-2B. It is therefore that the use of monoclonal antibody clone 
(19F) in this ELISA would be ideal and represents a useful alternative for 
routine measurement of 6-B-OHC in urine samples. 
In the study of CYP IIIA dependent enzyme activity, has been suggested 
that it is better to measure of the 6-S-OHC/cortisol ratio in urine, because this 
would be useful in correcting the day to day and inter individual variations in 
adrenal cortisol metabolism (Saenger etal” 1981; Poulsen etal； 1993) and 
that this would be a more accurate and dependable parameter for assessing 
the CYP IIIA activities. The ELISA developed in this study enables the accurate 
measurement of 6-R-OHC in urine samples by either monoclonal antibody 19F 
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and polyclonal antiserum R1-2B, which thus forms a first and important step in 
the determination of 6-R-OHC/cortisol ratio. It would therefore be expected that 
specific antibodies against cortisol could be raised based on the method 
described in this study. The resulting ELISA methods using specific antibodies 
against 6-R-OHC and cortisol would provide a useful screening method for 
monitoring human CYP IIIA enzyme activities. 
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